ПОЛУЧЕННЫЕ ГЕННО-ИНЖЕНЕРНЫМИ МЕТОДАМИ АНТИТЕЛА К CD200R И ВАРИАНТЫ ИХ ПРИМЕНЕНИЯ

Abstract

In some aspects, provided herein are antibodies or antigen-binding fragments that bind to CD200R, a glycoprotein receptor present on cell surfaces. Antibodies or antigen-binding fragments provided herein, in some cases, agonize CD200R signaling pathway that inhibits inflammation and immune response. In other aspects, provided herein are compositions, methods of use, methods of making, polynucleotides, vectors, host cells, and kits relating to antibodies or antigen-binding fragments that bind to CD200R.

Description

ENGINEERED CD200R ANTIBODIES AND USES THEREOFCROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit under 35 U.S.C. § 119(e) of U.S. Provisional Application No. 63 / 328,015, filed on April 6, 2022, and U.S. Provisional Application No. 63 / 348,532, filed on June 3, 2022, which are hereby incorporated herein by reference in their entireties for all purposes.SEQUENCE LISTING

[0002] The instant application contains a Sequence Listing which has been submitted electronically in .XML file format and is hereby incorporated by reference in its entirety. Said .XML copy, created on March 31, 2023, is named 210196-209003_PCT.xml and is 112,069 bytes in size.SUMMARY

[0003] Disclosed herein, in some aspects, is an antibody or an antigen-binding fragment thereof that specifically binds CD200R, comprising a heavy chain that comprises at least one heavy chain complementarity determining region (CDR) as set forth in any of SEQ ID NO: 3, 4, 41, 5, 11, 12, 13, 19, 20, 21, 27, 28, 29, 35, 36, 37, 69, 70, or 91, with from 0 to 3 amino acid modifications.

[0004] Disclosed herein, in some aspects, is an antibody or an antigen-binding fragment thereof that specifically binds CD200R, comprising a heavy chain and a light chain, wherein the heavy chain comprises a heavy chain variable region that comprises heavy chain complementarity determining region 1 (CDRH1), CDRH2, and CDRH3, and wherein CDRH1, CDRH2, and CDRH3 comprise the sequence as set forth in (a) SEQ ID NOs: 3, 41, and 70, respectively, each with 0 to 3 amino acid modifications, such as 0, 1, 2, or 3 modifications; (b) SEQ ID NOs: 3, 41, and 69, respectively, each with 0 to 3 amino acid modifications, such as 0, 1, 2, or 3 modifications; (c) SEQ ID NOs: 3, 4, and 5, respectively, each with 0 to 3 amino acid modifications, such as 0, 1, 2, or 3 modifications; (d) SEQ ID NOs: 3, 41, and 5, respectively, each with 0 to 3 amino acid modifications, such as 0, 1, 2, or 3 modifications; (e) SEQ ID NOs: 11, 12, and 13, respectively, each with 0 to 3 amino acid modifications, such as 0, 1, 2, or 3 modifications; (f) SEQ ID NOs: 19, 20, and 21, respectively, each with 0 to 3 amino acid modifications, such as 0, 1, 2, or 3 modifications; (g) SEQ ID NOs: 27, 28, and 29, respectively, each with 0 to 3 amino acid modifications, such as 0, 1, 2, or 3 modifications; or (h) SEQ IDNOs: 35, 36, and 37, respectively, each with 0 to 3 amino acid modifications, such as 0, 1, 2, or 3 modifications.

[0005] Disclosed herein, in some aspects, is an antibody or an antigen-binding fragment thereof that specifically binds CD200R, comprising a light chain that comprises at least one light chain complementarity determining region (CDR) as set forth in any of SEQ ID NO: 6, 7, 8, 14, 15, 16, 22, 23, 24, 30, 31, 32, 38, 39, 40, 67, 68, or 87 to 91, with from 0 to 3 amino acid modifications.

[0006] Disclosed herein, in some aspects, is an antibody or an antigen-binding fragment thereof, comprising a heavy chain and a light chain, wherein the light chain comprises a light chain variable region that comprises light chain complementarity determining region 1 (CDRL1), CDRL2, and CDRL3, and wherein CDRL1, CDRL2, and CDRL3 comprise the sequence as set forth in (a) SEQ ID NOs: 6, 7, and 8, respectively, each with 0 to 3 amino acid modifications, such as 0, 1, 2, or 3 modifications; (b) SEQ ID NOs: 14, 15, and 16, respectively, each with 0 to 3 amino acid modifications, such as 0, 1, 2, or 3 modifications; (c) SEQ ID NOs: 22, 23, and 24, respectively, each with 0 to 3 amino acid modifications, such as 0, 1, 2, or 3 modifications; (d) SEQ ID NOs: 30, 31, and 32, respectively, each with 0 to 3 amino acid modifications, such as 0,1, 2, or 3 modifications; (e) SEQ ID NOs: 38, 39, and 40, respectively, each with 0 to 3 amino acid modifications, such as 0, 1, 2, or 3 modifications; (f) SEQ ID NOs: 6, 67, and 8, respectively, each with 0 to 3 amino acid modifications, such as 0, 1, 2, or 3 modifications; or (g) SEQ ID NOs: 6, 68, and 8, respectively, each with 0 to 3 amino acid modifications, such as 0, 1,2, or 3 modifications.

[0007] Disclosed herein, in some aspects, is an antibody or an antigen-binding fragment thereof that specifically binds CD200R, comprising: (a) a heavy chain that comprises at least one heavy chain CDR as set forth in any of SEQ ID NO: 3, 4, 41, 5, 69, or 70, with from 0 to 3 amino acid modifications, and a light chain that comprises at least one light chain CDR as set forth in any of SEQ ID NO: 6, 7, or 8, with from 0 to 3 amino acid modifications; (b) a heavy chain that comprises at least one heavy chain CDR as set forth in any of SEQ ID NO: 3, 4, 41, 5, 69, or 70, with from 0 to 3 amino acid modifications, and a light chain that comprises at least one light chain CDR as set forth in any of SEQ ID NO: 6, 67, or 8, with from 0 to 3 amino acid modifications; (c) a heavy chain that comprises at least one heavy chain CDR as set forth in any of SEQ ID NO: 3, 4, 41, 5, 69, or 70, with from 0 to 3 amino acid modifications, and a light chain that comprises at least one light chain CDR as set forth in any of SEQ ID NO: 6, 68, or 8, with from 0 to 3 amino acid modifications; (d) a heavy chain that comprises at least one heavy chain CDR as set forth in any of SEQ ID NO: 3, 41, or 70, with from 0 to 3 amino acid modifications, and a light chain that comprises at least one light chain CDR as set forth in any of SEQ ID NO: 6, 67, or 8, with from 0 to 3 amino acid modifications; (e) a heavy chain thatcomprises at least one heavy chain CDR as set forth in any of SEQ ID NO: 3, 41, or 69, with from 0 to 3 amino acid modifications, and a light chain that comprises at least one light chain CDR as set forth in any of SEQ ID NO: 6, 67, or 8, with from 0 to 3 amino acid modifications; (f) a heavy chain that comprises at least one heavy chain CDR as set forth in any of SEQ ID NO: 11, 12, or 13, with from 0 to 3 amino acid modifications, and a light chain that comprises at least one light chain CDR as set forth in any of SEQ ID NO: 14, 15, or 16, with from 0 to 3 amino acid modifications; (g) a heavy chain that comprises at least one heavy chain CDR as set forth in any of SEQ ID NO: 19, 20, or 21, with from 0 to 3 amino acid modifications, and a light chain that comprises at least one light chain CDR as set forth in any of SEQ ID NO: 22, 23, or 24, with from 0 to 3 amino acid modifications; (h) a heavy chain that comprises at least one heavy chain CDR as set forth in any of SEQ ID NO: 27, 28, or 29, with from 0 to 3 amino acid modifications, and a light chain that comprises at least one light chain CDR as set forth in any of SEQ ID NO: 30, 31, or 32, with from 0 to 3 amino acid modifications; or (i) a heavy chain that comprises at least one heavy chain CDR as set forth in any of SEQ ID NO: 35, 36, or 37, with from 0 to 3 amino acid modifications, and a light chain that comprises at least one light chain CDR as set forth in any of SEQ ID NO: 38, 39, or 40, with from 0 to 3 amino acid modifications.

[0008] Disclosed herein, in some aspects, is an antibody or an antigen-binding fragment thereof, comprising a heavy chain and a light chain, wherein: (1) the heavy chain comprises a heavy chain variable region that comprises heavy chain complementarity determining region 1 (CDRH1), CDRH2, and CDRH3, wherein CDRH1, CDRH2, and CDRH3 comprise the sequence as set forth in SEQ ID NOs: 3, 41, and 70, respectively, each with 0 to 3 amino acid modifications, such as 0, 1, 2, or 3 modifications; and the light chain comprises a light chain variable region that comprises light chain complementarity determining region 1 (CDRL1), CDRL2, and CDRL3, wherein CDRL1, CDRL2, and CDRL3 comprise the sequence as set forth in SEQ ID NOs: 6, 67, and 8, respectively, each with 0 to 3 amino acid modifications, such as 0, 1, 2, or 3 modifications; (2) the heavy chain comprises a heavy chain variable region that comprises heavy chain complementarity determining region 1 (CDRH1), CDRH2, and CDRH3, wherein CDRH1, CDRH2, and CDRH3 comprise the sequence as set forth in SEQ ID NOs: 3, 41, and 5, respectively, each with 0 to 3 amino acid modifications, such as 0, 1, 2, or 3 modifications; and the light chain comprises a light chain variable region that comprises light chain complementarity determining region 1 (CDRL1), CDRL2, and CDRL3, wherein CDRL1, CDRL2, and CDRL3 comprise the sequence as set forth in SEQ ID NOs: 6, 67, and 8, respectively, each with 0 to 3 amino acid modifications, such as 0, 1, 2, or 3 modifications; (3) the heavy chain comprises a heavy chain variable region that comprises heavy chain complementarity determining region 1 (CDRH1), CDRH2, and CDRH3, wherein CDRH1,CDRH2, and CDRH3 comprise the sequence as set forth in SEQ ID NOs: 3, 4, and 5, respectively, each with 0 to 3 amino acid modifications, such as 0, 1, 2, or 3 modifications; and the light chain comprises a light chain variable region that comprises light chain complementarity determining region 1 (CDRL1), CDRL2, and CDRL3, wherein CDRL1, CDRL2, and CDRL3 comprise the sequence as set forth in SEQ ID NOs: 6, 7, and 8, respectively, each with 0 to 3 amino acid modifications, such as 0, 1, 2, or 3 modifications; (4) the heavy chain comprises a heavy chain variable region that comprises heavy chain CDRH1, CDRH2, and CDRH3, and wherein CDRH1, CDRH2, and CDRH3 comprise the sequence as set forth in SEQ ID NOs: 3, 41, and 5, respectively, each with 0 to 3 amino acid modifications, such as 0, 1, 2, or 3 modifications; and the light chain comprises a light chain variable region that comprises CDRL1, CDRL2, and CDRL3, and wherein CDRL1, CDRL2, and CDRL3 comprise the sequence as set forth in SEQ ID NOs: 6, 7, and 8, respectively, each with 0 to 3 amino acid modifications, such as 0, 1, 2, or 3 modifications; (5) the heavy chain comprises a heavy chain variable region that comprises CDRH1, CDRH2, and CDRH3, and wherein CDRH1, CDRH2, and CDRH3 comprise the sequence as set forth in SEQ ID NOs: 11, 12, and 13, respectively, each with 0 to 3 amino acid modifications, such as 0, 1, 2, or 3 modifications; and the light chain comprises a light chain variable region that comprises CDRL1, CDRL2, and CDRL3, and wherein CDRL1, CDRL2, and CDRL3 comprise the sequence as set forth in SEQ ID NOs: 14, 15, and 16, respectively, each with 0 to 3 amino acid modifications, such as 0, 1, 2, or 3 modifications; (6) the heavy chain comprises a heavy chain variable region that comprises CDRH1, CDRH2, and CDRH3, and wherein CDRH1, CDRH2, and CDRH3 comprise the sequence as set forth in SEQ ID NOs: 19, 20, and 21, respectively, each with 0 to 3 amino acid modifications, such as 0, 1, 2, or 3 modifications; and the light chain comprises a light chain variable region that comprises CDRL1, CDRL2, and CDRL3, and wherein CDRL1, CDRL2, and CDRL3 comprise the sequence as set forth in SEQ ID NOs: 22, 23, and 24, respectively, each with 0 to 3 amino acid modifications, such as 0, 1, 2, or 3 modifications; (7) the heavy chain comprises a heavy chain variable region that comprises CDRH1, CDRH2, and CDRH3, and wherein CDRH1, CDRH2, and CDRH3 comprise the sequence as set forth in SEQ ID NOs: 27, 28, and 29, respectively, each with 0 to 3 amino acid modifications, such as 0, 1, 2, or 3 modifications; and the light chain comprises a light chain variable region that comprises CDRL1, CDRL2, and CDRL3, and wherein CDRL1, CDRL2, and CDRL3 comprise the sequence as set forth in SEQ ID NOs: 30, 31, and 32, respectively, each with 0 to 3 amino acid modifications, such as 0, 1, 2, or 3 modifications; (8) the heavy chain comprises a heavy chain variable region that comprises CDRH1, CDRH2, and CDRH3, and wherein CDRH1, CDRH2, and CDRH3 comprise the sequence as set forth in SEQ ID NOs: 35, 36, and 37, respectively, each with 0 to 3 amino acid modifications, such as 0, 1, 2,or 3 modifications; and the light chain comprises a light chain variable region that comprises CDRL1, CDRL2, and CDRL3, and wherein CDRL1, CDRL2, and CDRL3 comprise the sequence as set forth in SEQ ID NOs: 38, 39, and 40, respectively, each with 0 to 3 amino acid modifications, such as 0, 1, 2, or 3 modifications; (9) the heavy chain comprises a heavy chain variable region that comprises heavy chain complementarity determining region 1 (CDRH1), CDRH2, and CDRH3, wherein CDRH1, CDRH2, and CDRH3 comprise the sequence as set forth in SEQ ID NOs: 3, 4, and 5, respectively, each with 0 to 3 amino acid modifications, such as 0, 1, 2, or 3 modifications; and the light chain comprises a light chain variable region that comprises light chain complementarity determining region 1 (CDRL1), CDRL2, and CDRL3, wherein CDRL1, CDRL2, and CDRL3 comprise the sequence as set forth in SEQ ID NOs: 6, 67, and 8, respectively, each with 0 to 3 amino acid modifications, such as 0, 1, 2, or 3 modifications; or (10) the heavy chain comprises a heavy chain variable region that comprises heavy chain complementarity determining region 1 (CDRH1), CDRH2, and CDRH3, wherein CDRH1, CDRH2, and CDRH3 comprise the sequence as set forth in SEQ ID NOs: 3, 4, and 5, respectively, each with 0 to 3 amino acid modifications, such as 0, 1, 2, or 3 modifications; and the light chain comprises a light chain variable region that comprises light chain complementarity determining region 1 (CDRL1), CDRL2, and CDRL3, wherein CDRL1, CDRL2, and CDRL3 comprise the sequence as set forth in SEQ ID NOs: 6, 68, and 8, respectively, each with 0 to 3 amino acid modifications, such as 0, 1, 2, or 3 modifications.

[0009] Disclosed herein, in some aspects, is an antibody or an antigen-binding fragment thereof, comprising a heavy chain and a light chain, wherein: the heavy chain comprises a heavy chain variable region that comprises heavy chain complementarity determining region 1 (CDRH1), CDRH2, and CDRH3, wherein CDRH1, CDRH2, and CDRH3 comprise the sequence as set forth in SEQ ID NOs: 3, 41, and 69, respectively, each with 0 to 3 amino acid modifications, such as 0, 1, 2, or 3 modifications; and the light chain comprises a light chain variable region that comprises light chain complementarity determining region 1 (CDRL1), CDRL2, and CDRL3, wherein CDRL1, CDRL2, and CDRL3 comprise the sequence as set forth in SEQ ID NOs: 6, 90, and 8, respectively, each with 0 to 3 amino acid modifications, such as 0, 1, 2, or 3 modifications. In some embodiments, X at position 1 of SEQ ID NO: 69 is M. In some embodiments, X at position 1 of SEQ ID NO: 69 is G. In some embodiments, X at position 7 of SEQ ID NO: 90 is D.

[0010] Disclosed herein is an antibody or antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain variable region (HCVR) and a light chain variable region (LCVR), wherein: (a) the HCVR comprises heavy chain complementarity determining region 1 (CDRH1), CDRH2, and CDRH3, and wherein CDRH1,CDRH2, and CDRH3 comprise the sequence as set forth in SEQ ID NOs: 3, 41, and 70, respectively, each with 0 to 3 amino acid modifications, such as 0, 1, 2, or 3 modifications; and (b) the LCVR comprises light chain complementarity determining region 1 (CDRL1), CDRL2, and CDRL3, and wherein CDRL1, CDRL2, and CDRL3 comprise the sequence as set forth in SEQ ID NOs: 6, 67, and 8, respectively, each with 0 to 3 amino acid modifications, such as 0, 1, 2, or 3 modifications. In some embodiments, the HCVR comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 72, and the LCVR comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 65. In some embodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 72, with from 0 to 10 amino acid modifications, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid modifications, and the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 65, with from 0 to 10 amino acid modifications, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid modifications.

[0011] Disclosed herein is an antibody or antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain variable region (HCVR) and a light chain variable region (LCVR), wherein: (a) the HCVR comprises heavy chain complementarity determining region 1 (CDRH1), CDRH2, and CDRH3, and wherein CDRH1, CDRH2, and CDRH3 comprise the sequence as set forth in SEQ ID NOs: 3, 41, and 5, respectively, each with 0 to 3 amino acid modifications, such as 0, 1, 2, or 3 modifications; and (b) the LCVR comprises light chain complementarity determining region 1 (CDRL1), CDRL2, and CDRL3, and wherein CDRL1, CDRL2, and CDRL3 comprise the sequence as set forth in SEQ ID NOs: 6, 67, and 8, respectively, each with 0 to 3 amino acid modifications, such as 0, 1, 2, or 3 modifications. In some embodiments, the HCVR comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 71, and the LCVR comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 65. In some embodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 71, with from 0 to 10 amino acid modifications, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid modifications, and the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 65, with from 0 to 10 amino acid modifications, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid modifications.

[0012] Disclosed herein, in some aspects, is an antibody or an antigen-binding fragment thereof, comprising a heavy chain and a light chain, wherein: (a) the heavy chain comprises a heavy chain variable region that comprises (i) a heavy chain complementarity determining region1 (CDRH1) comprising the sequence as set forth in SEQ ID NO: 92, (ii) a CDRH2 comprising the sequence as set forth in SEQ ID NO: 41, and (iii) a CDRH3 comprising the sequence as set forth in SEQ ID NO: 69; and (b) the light chain comprises a light chain variable region that comprises (i) a light chain complementarity determining region 1 (CDRL1) comprising the sequence as set forth in SEQ ID NO: 6, (ii) a CDRL2 comprising a sequence selected from SEQ ID NOs: 87 to 90, and (iii) a CDRL3 comprising the sequence as set forth in SEQ ID NO: 91. In some embodiments, X at position 1 of SEQ ID NO: 69 is M In some embodiments, X at position 1 of SEQ ID NO: 69 is G. In some embodiments, X at position 8 of SEQ ID NO: 91 is W. In some embodiments, X at position 8 of SEQ ID NO: 91 is F. In some embodiments, X at position 3 of SEQ ID NO: 92 is W. In some embodiments, X at position 3 of SEQ ID NO: 92 is F. In some embodiments, X at position 1 of SEQ ID NO: 87, 88, or 89 is G. In some embodiments, X at position 1 of SEQ ID NO: 87, 88, or 89 is L. In some embodiments, X at position 2 of SEQ ID NO: 87 or 90 is A. In some embodiments, X at position 2 of SEQ ID NO: 87 or 90 is G. In some embodiments, X at position 3 of SEQ ID NO: 87 or 88 is S. In some embodiments, X at position 3 of SEQ ID NO: 87 or 88 is V. In some embodiments, X at position 7 of SEQ ID NO: 87, 88, 89, or 90 is D. In some embodiments, X at position 7 of SEQ ID NO: 87, 88, 89, or 90 is S. In some embodiments, X at position 7 of SEQ ID NO: 87, 88, 89, or 90 is T. In some embodiments, the HCVR comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 72, and the LCVR comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 65. In some embodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 72, with from 0 to 10 amino acid modifications, and the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 65, with from 0 to 10 amino acid modifications. In some embodiments, the HCVR comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 71, and the LCVR comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 65. In some embodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 71, with from 0 to 10 amino acid modifications, and the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 65, with from 0 to 10 amino acid modifications. In some embodiments, the HCVR comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 45, and the LCVR comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 65. In someembodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 45, with from 0 to 10 amino acid modifications, and the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 65, with from 0 to 10 amino acid modifications. In some embodiments, the HCVR comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 93, and the LCVR comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 94. In some embodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 93, with from 0 to 10 amino acid modifications, such as from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 modifications, and the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 94, with from 0 to 10 amino acid modifications, such as from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 modifications. In some embodiments, X at position 1 of SEQ ID NO: 93 is D. In some embodiments, X at position 1 of SEQ ID NO: 93 is E. In some embodiments, X at position 33 of SEQ ID NO: 93 is W. In some embodiments, X at position 33 of SEQ ID NO: 93 is F. In some embodiments, X at position 99 of SEQ ID NO: 93 is M. In some embodiments, X at position 99 of SEQ ID NO: 93 is G. In some embodiments, X at position 50 of SEQ ID NO: 94 is G. In some embodiments, X at position 50 of SEQ ID NO: 94 is L. In some embodiments, X at position 51 of SEQ ID NO: 94 is A. In some embodiments, X at position 51 of SEQ ID NO: 94 is G. In some embodiments, X at position 52 of SEQ ID NO: 94 is S. In some embodiments, X at position 52 of SEQ ID NO: 94 is V. In some embodiments, X at position 56 of SEQ ID NO: 94 is D. In some embodiments, X at position 56 of SEQ ID NO: 94 is S. In some embodiments, X at position 56 of SEQ ID NO: 94 is T. In some embodiments, X at position 96 of SEQ ID NO: 94 is W. In some embodiments, X at position 96 of SEQ ID NO: 94 is F. In some embodiments, the LCVR is linked to a light chain constant region comprising an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 62. In some embodiments, the light chain variable region is linked to a light chain constant region comprising an amino acid sequence as set forth in SEQ ID NO: 62, with from 0 to 10 amino acid modifications. In some embodiments, the light chain variable region is linked to a light chain constant region comprising an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 64. In some embodiments, the light chain variable region is linked to a light chain constant region comprising an amino acid sequence as set forth in SEQ ID NO: 64, with from 0 to 10 amino acid modifications. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 61. In someembodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence as set forth in SEQ ID NO: 61, with from 0 to 10 amino acid modifications. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 63. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence as set forth in SEQ ID NO: 63, with from 0 to 10 amino acid modifications. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 75. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence as set forth in SEQ ID NO: 75, with from 0 to 10 amino acid modifications. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 76. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence as set forth in SEQ ID NO: 76, with from 0 to 10 amino acid modifications. In some embodiments, the HCVR is linked to a heavy chain constant region, wherein the heavy chain constant region comprises an Fc region that comprises one or more of the following amino acids: alanine (A) at position 234, alanine (A) at position 235, aspartic acid (D) at position 236, aspartic acid (D) at position 237, aspartic acid (D) at position 238, alanine (A) at position 265, glutamic acid (E) at position 267, glycine (G) at position 271, arginine (R) at position 330, alanine (A) at position 332, or alanine (A) at position 297 (numbering according to EU Index). In some embodiments, the Fc region comprises an aspartic acid (D) at position 238 (EU Index). In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 77. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence as set forth in SEQ ID NO: 77, with from 0 to 10 amino acid modifications. In some embodiments, X at position 121 of SEQ ID NO: 77 is D. In some embodiments, X at position 121 of SEQ ID NO: 77 is P. In some embodiments, X at position 329 of SEQ ID NO: 77 is G. In some embodiments, X at position 329 of SEQ ID NO: 77 is absent. In some embodiments, X at position 330 of SEQ ID NO: 77 is K. In some embodiments, X at position 330 of SEQ ID NO: 77 is absent. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 78. In some embodiments, the HCVR is linked to a heavy chainconstant region comprising an amino acid sequence as set forth in SEQ ID NO: 78, with from 0 to 10 amino acid modifications. In some embodiments, X at position 108 of SEQ ID NO: 78 is S. In some embodiments, X at position 108 of SEQ ID NO: 78 is P. In some embodiments, X at position 326 of SEQ ID NO: 78 is G. In some embodiments, X at position 326 of SEQ ID NO: 78 is absent. In some embodiments, X at position 327 of SEQ ID NO: 78 is K. In some embodiments, X at position 327 of SEQ ID NO: 78 is absent.

[0013] Disclosed herein, in some aspects, is an antibody or an antigen-binding fragment thereof, comprising a heavy chain and a light chain, wherein: the heavy chain comprises a heavy chain variable region that comprises heavy chain complementarity determining region 1 (CDRH1), CDRH2, and CDRH3, wherein CDRH1, CDRH2, and CDRH3 comprise the sequence as set forth in SEQ ID NOs: 3, 41, and 69, respectively, each with 0 to 3 amino acid modifications; and the light chain comprises a light chain variable region that comprises light chain complementarity determining region 1 (CDRL1), CDRL2, and CDRL3, wherein CDRL1, CDRL2, and CDRL3 comprise the sequence as set forth in SEQ ID NOs: 6, 90, and 8, respectively, each with 0 to 3 amino acid modifications. In some embodiments, X at position 1 of SEQ ID NO: 69 is M. In some embodiments, X at position 1 of SEQ ID NO: 69 is G. In some embodiments, X at position 7 of SEQ ID NO: 90 is D. In some embodiments, X at position 7 of SEQ ID NO: 90 is S. In some embodiments, X at position 7 of SEQ ID NO: 90 is T. In some embodiments, the HCVR comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 72, and the LCVR comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 65. In some embodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 72, with from 0 to 10 amino acid modifications, and the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 65, with from 0 to 10 amino acid modifications. In some embodiments, the HCVR comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 71, and the LCVR comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 65. In some embodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 71, with from 0 to 10 amino acid modifications, and the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 65, with from 0 to 10 amino acid modifications. In some embodiments, the HCVR comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 45, and the LCVR comprises an amino acid sequence having at least 90%, 95%, 96%, 97%,98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 65. In some embodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 45, with from 0 to 10 amino acid modifications, and the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 65, with from 0 to 10 amino acid modifications. In some embodiments, the HCVR comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 93, and the LCVR comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 94. In some embodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 93, with from 0 to 10 amino acid modifications, such as from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 modifications, and the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 94, with from 0 to 10 amino acid modifications, such as from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 modifications. In some embodiments, X at position 1 of SEQ ID NO: 93 is D. In some embodiments, X at position 1 of SEQ ID NO: 93 is E. In some embodiments, X at position 33 of SEQ ID NO: 93 is W. In some embodiments, X at position 33 of SEQ ID NO: 93 is F. In some embodiments, X at position 99 of SEQ ID NO: 93 is M. In some embodiments, X at position 99 of SEQ ID NO: 93 is G. In some embodiments, X at position 50 of SEQ ID NO: 94 is G. In some embodiments, X at position 50 of SEQ ID NO: 94 is L. In some embodiments, X at position 51 of SEQ ID NO: 94 is A. In some embodiments, X at position 51 of SEQ ID NO: 94 is G. In some embodiments, X at position 52 of SEQ ID NO: 94 is S. In some embodiments, X at position 52 of SEQ ID NO: 94 is V. In some embodiments, X at position 56 of SEQ ID NO: 94 is D. In some embodiments, X at position 56 of SEQ ID NO: 94 is S. In some embodiments, X at position 56 of SEQ ID NO: 94 is T. In some embodiments, X at position 96 of SEQ ID NO: 94 is W. In some embodiments, X at position 96 of SEQ ID NO: 94 is F. In some embodiments, the LCVR is linked to a light chain constant region comprising an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 62. In some embodiments, the light chain variable region is linked to a light chain constant region comprising an amino acid sequence as set forth in SEQ ID NO: 62, with from 0 to 10 amino acid modifications. In some embodiments, the light chain variable region is linked to a light chain constant region comprising an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 64. In some embodiments, the light chain variable region is linked to a light chain constant region comprising an amino acid sequence as set forth in SEQ ID NO: 64, with from 0 to 10 amino acid modifications. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 61. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence as set forth in SEQ ID NO: 61, with from 0 to 10 amino acid modifications. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 63. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence as set forth in SEQ ID NO: 63, with from 0 to 10 amino acid modifications. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 75. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence as set forth in SEQ ID NO: 75, with from 0 to 10 amino acid modifications. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 76. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence as set forth in SEQ ID NO: 76, with from 0 to 10 amino acid modifications. In some embodiments, the HCVR is linked to a heavy chain constant region, wherein the heavy chain constant region comprises an Fc region that comprises one or more of the following amino acids: alanine (A) at position 234, alanine (A) at position 235, aspartic acid (D) at position 236, aspartic acid (D) at position 237, aspartic acid (D) at position 238, alanine (A) at position 265, glutamic acid (E) at position 267, glycine (G) at position 271, arginine (R) at position 330, alanine (A) at position 332, or alanine (A) at position 297 (numbering according to EU Index). In some embodiments, the Fc region comprises an aspartic acid (D) at position 238 (EU Index). In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 77. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence as set forth in SEQ ID NO: 77, with from 0 to 10 amino acid modifications. In some embodiments, X at position 121 of SEQ ID NO: 77 is D. In some embodiments, X at position 121 of SEQ ID NO: 77 is P. In some embodiments, X at position 329 of SEQ ID NO: 77 is G. In some embodiments, X at position 329 of SEQ ID NO: 77 is absent. In some embodiments, X at position 330 of SEQ ID NO: 77 is K. In some embodiments, X at position 330 of SEQ ID NO: 77 is absent. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequenceas set forth in SEQ ID NO: 78. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence as set forth in SEQ ID NO: 78, with from 0 to 10 amino acid modifications. In some embodiments, X at position 108 of SEQ ID NO: 78 is S. In some embodiments, X at position 108 of SEQ ID NO: 78 is P. In some embodiments, X at position 326 of SEQ ID NO: 78 is G. In some embodiments, X at position 326 of SEQ ID NO: 78 is absent. In some embodiments, X at position 327 of SEQ ID NO: 78 is K. In some embodiments, X at position 327 of SEQ ID NO: 78 is absent.

[0014] In some cases, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region that comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 1, 9, 17, 25, 33, 42, 43, 44, 45, 46, 47, 71, 72, or 93.

[0015] In some cases, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region that comprises an amino acid sequence as set forth in SEQ ID NO: 1, 9, 17, 25, 33, 42, 43, 44, 45, 46, 47, 71, 72, or 93, with from 0 to 3 amino acid modifications.

[0016] In some cases, the antibody or antigen-binding fragment thereof comprises a light chain variable region that comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 2, 10, 18, 26, 34, 48, 49, 50, 51, 52, 65, 66, or 94.

[0017] In some cases, the antibody or antigen-binding fragment thereof comprises a light chain variable region that comprises an amino acid sequence as set forth in SEQ ID NO: 2, 10, 18, 26, 34, 48, 49, 50, 51, 52, 65, 66, or 94, with from 0 to 3 amino acid modifications.

[0018] In some cases, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region and a light chain variable region, wherein: (a) the heavy chain variable region comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 72, and the light chain variable region comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 65; (b) the heavy chain variable region comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 71, and the light chain variable region comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 65; (c) the heavy chain variable region comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 1, and the light chain variable region comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequenceidentity to the amino acid sequence as set forth in SEQ ID NO: 2; (d) the heavy chain variable region comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 9, and the light chain variable region comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 10; (e) the heavy chain variable region comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 17, and the light chain variable region comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 18; (f) the heavy chain variable region comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 25, and the light chain variable region comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 26; (g) the heavy chain variable region comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 33, and the light chain variable region comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 34; (h) the heavy chain variable region comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in any one of SEQ ID NOs: 1, 42, 43, 44, 45, 46, 47, 71, 72, or 93 and the light chain variable region comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 2, 48, 49, 50, 51, 52, 65, 66, or 94; or (i) the heavy chain variable region comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in any one of SEQ ID NOs: 42, 43, 44, 45, 46, 47, 71, 72, or 93 and the light chain variable region comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NOS: 48, 49, 50, 51, 52, 65, 66, or 94.

[0019] In some cases, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region and a light chain variable region, wherein: (a) the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 72, with from 0 to 10 amino acid modifications, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid modifications, and the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 65, with from 0 to 10 amino acid modifications, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acidmodifications; (b) the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 71, with from 0 to 10 amino acid modifications, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid modifications, and the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 65, with from 0 to 10 amino acid modifications, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid modifications; (c) the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 1, with from 0 to 10 amino acid modifications, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid modifications, and the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 2, with from 0 to 10 amino acid modifications, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid modifications; (d) the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 9, with from 0 to 10 amino acid modifications, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid modifications, and the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 10, with from 0 to 10 amino acid modifications, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid modifications; (e) the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 17, with from 0 to 10 amino acid modifications, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid modifications, and the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 18, with from 0 to 10 amino acid modifications, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid modifications; (f) the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 25, with from 0 to 10 amino acid modifications, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid modifications, and the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 26, with from 0 to 10 amino acid modifications, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid modifications; (g) the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 33, with from 0 to 10 amino acid modifications, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid modifications, and the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 34, with from 0 to 10 amino acid modifications, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid modifications; (h) the heavy chain variable region comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 1, 42, 43, 44, 45, 46, 47, 71, 72, or 93 with from 0 to 10 amino acid modifications, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid modifications, and the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NOs: 2, 48, 49, 50, 51, 52, 65, 66, or 94, with from 0 to 10 amino acid modifications, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid modifications; or (i) the heavy chain variable region comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 42, 43, 44, 45, 46, 47, 71, 72, or 93 with from 0 to 10 amino acid modifications, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid modifications, and the light chain variable region comprises an amino acidsequence as set forth in SEQ ID NOs: 48, 49, 50, 51, 52, 65, 66, or 94 with from 0 to 10 amino acid modifications, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid modifications.

[0020] Disclosed herein, in some aspects, is an antibody or an antigen-binding fragment thereof of that specifically binds CD200R, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain that comprises a heavy chain variable region, and wherein the heavy chain variable region comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 1, 9, 17, 25, 33, 42, 43, 44, 45, 46, 47, 71, 72, or 93.

[0021] Disclosed herein, in some aspects, is an antibody or an antigen-binding fragment thereof of that specifically binds CD200R, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain variable region, and wherein the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 1, 9, 17, 25, 33, 42, 43, 44, 45, 46, 47, 71, 72, or 93with from 0 to 10 amino acid modifications, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid modifications.

[0022] Disclosed herein, in some aspects, is an antibody or an antigen-binding fragment thereof of that specifically binds CD200R, wherein the antibody or antigen-binding fragment thereof comprises a light chain that comprises a light chain variable region, and wherein the light chain variable region comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 2, 10, 18, 26, 34, 48, 49, 50, 51, 52, 65, 66, or 94.

[0023] Disclosed herein, in some aspects, is an antibody or an antigen-binding fragment thereof of that specifically binds CD200R, wherein the antibody or antigen-binding fragment thereof comprises a light chain that comprises a light chain variable region, and wherein the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 2, 10, 18, 26, 34, 48, 49, 50, 51, 52, 65, 66, or 94, with from 0 to 10 amino acid modifications, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid modifications.

[0024] Disclosed herein, in some aspects, is an antibody or an antigen-binding fragment thereof of that specifically binds CD200R, comprising a heavy chain and a light chain, wherein the heavy chain comprises a heavy chain variable region, and the light chain comprises a light chain variable region, wherein: (a) the heavy chain variable region comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 72, and the light chain variable region comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 65; (b) the heavy chain variable region comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%,99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 71, and the light chain variable region comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 65; (c) the heavy chain variable region comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 1, and the light chain variable region comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 2; (d) the heavy chain variable region comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 9, and the light chain variable region comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 10; (e) the heavy chain variable region comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 17, and the light chain variable region comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 18; (f) the heavy chain variable region comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 25, and the light chain variable region comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 26; (g) the heavy chain variable region comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 33, and the light chain variable region comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 34; (h) the heavy chain variable region comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in any one of SEQ ID NOs: 1, 42, 43, 44, 45, 46, 47, 71, 72, or 93 and the light chain variable region comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 2, 48, 49, 50, 51, 52, 65, 66, or 94; or (i) the heavy chain variable region comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in any one of SEQ ID NOs: 42, 43, 44, 45, 46, 47, 71, 72, or 93 and the light chain variable region comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NOS: 48, 49, 50, 51, 52, 65, 66, or 94.

[0025] Disclosed herein, in some aspects, is an antibody or an antigen-binding fragment thereof of that specifically binds CD200R, comprising a heavy chain and a light chain, wherein the heavy chain comprises a heavy chain variable region and the light chain comprises a light chain variable region, wherein: (a) the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 72, with from 0 to 10 amino acid modifications, such as 1,2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid modifications, and the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 65, with from 0 to 10 amino acid modifications, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid modifications; (b) the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 71, with from 0 to 10 amino acid modifications, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid modifications, and the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 65, with from 0 to 10 amino acid modifications, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid modifications; (c) the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 1, with from 0 to 10 amino acid modifications, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid modifications, and the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 2, with from 0 to 10 amino acid modifications, such as 1, 2,3, 4, 5, 6, 7, 8, 9 or 10 amino acid modifications; (d) the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 9, with from 0 to 10 amino acid modifications, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid modifications, and the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 10, with from 0 to 10 amino acid modifications, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid modifications; (e) the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 17, with from 0 to 10 amino acid modifications, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid modifications, and the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 18, with from 0 to 10 amino acid modifications, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid modifications; (f) the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 25, with from 0 to 10 amino acid modifications, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid modifications, and the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 26, with from 0 to 10 amino acid modifications, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid modifications; (g) the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 33, with from 0 to 10 amino acid modifications, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid modifications, and the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 34, with from 0 to 10 amino acid modifications, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid modifications; (h) the heavy chain variable region comprises an amino acid sequence as set forthin any one of SEQ ID NOs: 1, 42, 43, 44, 45, 46, 47, 71, 72, or 93 with from 0 to 10 amino acid modifications, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid modifications, and the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NOs: 2, 48, 49, 50, 51, 52, 65, 66, or 94, with from 0 to 10 amino acid modifications, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid modifications; or (i) the heavy chain variable region comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 42, 43, 44, 45, 46, 47, 71, 72, or 93 with from 0 to 10 amino acid modifications, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid modifications, and the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NOs: 48, 49, 50, 51, 52, 65, 66, or 94 with from 0 to 10 amino acid modifications, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid modifications.

[0026] Disclosed herein is an antibody or antigen-binding fragment thereof comprising a heavy chain variable region (HCVR) and a light chain variable region (LCVR), wherein: (a) the HCVR comprises heavy chain complementarity determining region 1 (CDRH1), CDRH2, and CDRH3, and wherein CDRH1, CDRH2, and CDRH3 comprise the sequence as set forth in SEQ ID NOs: 3, 41, and 70, respectively, each with 0 to 3 amino acid modifications, such as 0, 1, 2, or 3 modifications; and (b) the LCVR comprises light chain complementarity determining region 1 (CDRL1), CDRL2, and CDRL3, and wherein CDRL1, CDRL2, and CDRL3 comprise the sequence as set forth in SEQ ID NOs: 6, 67, and 8, respectively, each with 0 to 3 amino acid modifications, such as 0, 1, 2, or 3 modifications. In some embodiments, the HCVR comprises heavy chain complementarity determining region 1 (CDRH1), CDRH2, and CDRH3, and wherein CDRH1, CDRH2, and CDRH3 comprise the sequence as set forth in SEQ ID NOs: 3, 41, and 70, respectively, each with 0 to 2 amino acid modifications. In some embodiments, the HCVR comprises heavy chain complementarity determining region 1 (CDRH1), CDRH2, and CDRH3, and wherein CDRH1, CDRH2, and CDRH3 comprise the sequence as set forth in SEQ ID NOs: 3, 41, and 70, respectively, each with 0 to 1 amino acid modifications. In some embodiments, the HCVR comprises heavy chain complementarity determining region 1 (CDRH1), CDRH2, and CDRH3, and wherein CDRH1, CDRH2, and CDRH3 comprise the sequence as set forth in SEQ ID NOs: 3, 41, and 70, respectively. In some embodiments, the LCVR comprises light chain complementarity determining region 1 (CDRL1), CDRL2, and CDRL3, and wherein CDRL1, CDRL2, and CDRL3 comprise the sequence as set forth in SEQ ID NOs: 6, 67, and 8, respectively, each with 0 to 2 amino acid modifications. In some embodiments, the LCVR comprises light chain complementarity determining region 1 (CDRL1), CDRL2, and CDRL3, and wherein CDRL1, CDRL2, and CDRL3 comprise the sequence as set forth in SEQ ID NOs: 6, 67, and 8, respectively, each with 0 to 1 amino acid modifications. In some embodiments, the LCVR comprises light chain complementarity determining region 1(CDRL1), CDRL2, and CDRL3, and wherein CDRL1, CDRL2, and CDRL3 comprise the sequence as set forth in SEQ ID NOs: 6, 67, and 8, respectively. In some embodiments, antibody or antigen-binding fragment thereof comprises an HCVR that comprises heavy chain complementarity determining region 1 (CDRH1), CDRH2, and CDRH3, and wherein CDRH1, CDRH2, and CDRH3 comprise the sequence as set forth in SEQ ID NOs: 3, 41, and 70, respectively, and an LCVR that comprises light chain complementarity determining region 1 (CDRL1), CDRL2, and CDRL3, and wherein CDRL1, CDRL2, and CDRL3 comprise the sequence as set forth in SEQ ID NOs: 6, 67, and 8, respectively. In some embodiments, the HCVR comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 72. In some embodiments, the HCVR comprises an amino acid sequence having at least 95% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 72. In some embodiments, the HCVR comprises an amino acid sequence having at least 97% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 72. In some embodiments, the HCVR comprises an amino acid sequence having at least 98% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 72. In some embodiments, the HCVR comprises an amino acid sequence having at least 99% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 72. In some embodiments, the HCVR comprises an amino acid sequence having 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 72. In some embodiments, the LCVR comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 65. In some embodiments, the LCVR comprises an amino acid sequence having at least 95% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 65. In some embodiments, the LCVR comprises an amino acid sequence having at least 97% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 65. In some embodiments, the LCVR comprises an amino acid sequence having at least 98% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 65. In some embodiments, the LCVR comprises an amino acid sequence having at least 99% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 65. In some embodiments, the LCVR comprises an amino acid sequence having 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 65. In some embodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 72, with from 0 to 10 amino acid modifications, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid modifications. In some embodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 72, with from 0 to 9 amino acid modifications. In some embodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 72, with from 0 to 8 amino acid modifications. In someembodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 72, with from 0 to 7 amino acid modifications. In some embodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 72, with from 0 to 6 amino acid modifications. In some embodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 72, with from 0 to 5 amino acid modifications. In some embodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 72, with from 0 to 4 amino acid modifications. In some embodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 72, with from 0 to 3 amino acid modifications. In some embodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 72, with from 0 to 2 amino acid modifications. In some embodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 72, with from 0 to 1 amino acid modifications. In some embodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 72. In some embodiments, the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 65, with from 0 to 10 amino acid modifications, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid modifications. In some embodiments, the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 65, with from 0 to 9 amino acid modifications. In some embodiments, the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 65, with from 0 to 8 amino acid modifications. In some embodiments, the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 65, with from 0 to 7 amino acid modifications. In some embodiments, the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 65, with from 0 to 6 amino acid modifications. In some embodiments, the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 65, with from 0 to 5 amino acid modifications. In some embodiments, the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 65, with from 0 to 4 amino acid modifications. In some embodiments, the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 65, with from 0 to 3 amino acid modifications. In some embodiments, the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 65, with from 0 to 2 amino acid modifications. In some embodiments, the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 65, with from 0 to 1 amino acid modifications. In some embodiments, the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 65.

[0027] Disclosed herein is an antibody or antigen-binding fragment thereof comprising a heavy chain variable region (HCVR) and a light chain variable region (LCVR), wherein: (a) the HCVR comprises heavy chain complementarity determining region 1 (CDRH1), CDRH2, and CDRH3, and wherein CDRH1, CDRH2, and CDRH3 comprise the sequence as set forth in SEQ ID NOs: 3, 41, and 5, respectively, each with 0 to 3 amino acid modifications, such as 0, 1, 2, or 3 modifications; and (b) the LCVR comprises light chain complementarity determining region 1(CDRL1), CDRL2, and CDRL3, and wherein CDRL1, CDRL2, and CDRL3 comprise the sequence as set forth in SEQ ID NOs: 6, 67, and 8, respectively, each with 0 to 3 amino acid modifications, such as 0, 1, 2, or 3 modifications. In some embodiments, the HCVR comprises heavy chain complementarity determining region 1 (CDRH1), CDRH2, and CDRH3, and wherein CDRH1, CDRH2, and CDRH3 comprise the sequence as set forth in SEQ ID NOs: 3, 41, and 5, respectively, each with 0 to 2 amino acid modifications. In some embodiments, the HCVR comprises heavy chain complementarity determining region 1 (CDRH1), CDRH2, and CDRH3, and wherein CDRH1, CDRH2, and CDRH3 comprise the sequence as set forth in SEQ ID NOs: 3, 41, and 5, respectively, each with 0 to 1 amino acid modifications. In some embodiments, the HCVR comprises heavy chain complementarity determining region 1 (CDRH1), CDRH2, and CDRH3, and wherein CDRH1, CDRH2, and CDRH3 comprise the sequence as set forth in SEQ ID NOs: 3, 41, and 5, respectively. In some embodiments, the LCVR comprises light chain complementarity determining region 1 (CDRL1), CDRL2, and CDRL3, and wherein CDRL1, CDRL2, and CDRL3 comprise the sequence as set forth in SEQ ID NOs: 6, 67, and 8, respectively, each with 0 to 2 amino acid modifications. In some embodiments, the LCVR comprises light chain complementarity determining region 1 (CDRL1), CDRL2, and CDRL3, and wherein CDRL1, CDRL2, and CDRL3 comprise the sequence as set forth in SEQ ID NOs: 6, 67, and 8, respectively, each with 0 to 1 amino acid modifications. In some embodiments, the LCVR comprises light chain complementarity determining region 1 (CDRL1), CDRL2, and CDRL3, and wherein CDRL1, CDRL2, and CDRL3 comprise the sequence as set forth in SEQ ID NOs: 6, 67, and 8, respectively. In some embodiments, antibody or antigen-binding fragment thereof comprises an HCVR that comprises heavy chain complementarity determining region 1 (CDRH1), CDRH2, and CDRH3, and wherein CDRH1, CDRH2, and CDRH3 comprise the sequence as set forth in SEQ ID NOs: 3, 41, and 5, respectively, and an LCVR that comprises light chain complementarity determining region 1 (CDRL1), CDRL2, and CDRL3, and wherein CDRL1, CDRL2, and CDRL3 comprise the sequence as set forth in SEQ ID NOs: 6, 67, and 8, respectively. In some embodiments, the HCVR comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 71. In some embodiments, the HCVR comprises an amino acid sequence having at least 95% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 71. In some embodiments, the HCVR comprises an amino acid sequence having at least 97% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 71. In some embodiments, the HCVR comprises an amino acid sequence having at least 98% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 71. In some embodiments, the HCVR comprises an amino acid sequencehaving at least 99% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 71. In some embodiments, the HCVR comprises an amino acid sequence having 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 71. In some embodiments, the LCVR comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 65. In some embodiments, the LCVR comprises an amino acid sequence having at least 95% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 65. In some embodiments, the LCVR comprises an amino acid sequence having at least 97% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 65. In some embodiments, the LCVR comprises an amino acid sequence having at least 98% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 65. In some embodiments, the LCVR comprises an amino acid sequence having at least 99% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 65. In some embodiments, the LCVR comprises an amino acid sequence having 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 65. In some embodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 71, with from 0 to 10 amino acid modifications, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid modifications. In some embodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 71, with from 0 to 9 amino acid modifications. In some embodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 71, with from 0 to 8 amino acid modifications. In some embodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 71, with from 0 to 7 amino acid modifications. In some embodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 71, with from 0 to 6 amino acid modifications. In some embodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 71, with from 0 to 5 amino acid modifications. In some embodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 71, with from 0 to 4 amino acid modifications. In some embodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 71, with from 0 to 3 amino acid modifications. In some embodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 71, with from 0 to 2 amino acid modifications. In some embodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 71, with from 0 to 1 amino acid modifications. In some embodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 71. In some embodiments, the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 65, with from 0 to 10 amino acid modifications, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid modifications. In some embodiments, the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 65, with from 0 to 9 amino acid modifications. In some embodiments, the LCVR comprises an amino acid sequence as set forthin SEQ ID NO: 65, with from 0 to 8 amino acid modifications. In some embodiments, the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 65, with from 0 to 7 amino acid modifications. In some embodiments, the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 65, with from 0 to 6 amino acid modifications. In some embodiments, the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 65, with from 0 to 5 amino acid modifications. In some embodiments, the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 65, with from 0 to 4 amino acid modifications. In some embodiments, the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 65, with from 0 to 3 amino acid modifications. In some embodiments, the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 65, with from 0 to 2 amino acid modifications. In some embodiments, the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 65, with from 0 to 1 amino acid modifications. In some embodiments, the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 65.

[0028] Disclosed herein is an antibody or antigen-binding fragment thereof comprising (a) a heavy chain that comprises a heavy chain variable region (HCVR), wherein the HCVR comprises 1 to 3 heavy chain CDRs as set forth in any of SEQ ID NO: 3, 4, 41, 5, 69, or 70, with from 0 to 3 amino acid modifications; and (b) a light chain that comprises a light chain variable region (LCVR), wherein the LCVR comprises 1 to 3 light chain CDRs as set forth in any of SEQ ID NO: 6, 67, or 8, with from 0 to 3 amino acid modifications.

[0029] Disclosed herein is an antibody or antigen-binding fragment thereof comprising (a) a heavy chain that comprises a heavy chain variable region (HCVR), wherein the HCVR comprises 1 to 3 heavy chain CDRs as set forth in any of SEQ ID NO: 3, 4, 41, 5, 69, or 70, with from 0 to 3 amino acid modifications; and (b) a light chain that comprises a light chain variable region (LCVR), wherein the LCVR comprises 1 to 3 light chain CDRs as set forth in any of SEQ ID NO: 6, 7, or 8, with from 0 to 3 amino acid modifications.

[0030] Disclosed herein is an antibody or antigen-binding fragment thereof comprising (a) a heavy chain that comprises a heavy chain variable region (HCVR), wherein the HCVR comprises 1 to 3 heavy chain CDRs as set forth in any of SEQ ID NO: 3, 4, 41, 5, 69, or 70, with from 0 to 3 amino acid modifications; and (b) a light chain that comprises a light chain variable region (LCVR), wherein the LCVR comprises 1 to 3 light chain CDRs as set forth in any of SEQ ID NO: 6, 68, or 8, with from 0 to 3 amino acid modifications.

[0031] Disclosed herein is an antibody or antigen-binding fragment thereof comprising (a) a heavy chain that comprises a heavy chain variable region (HCVR), wherein the HCVR comprises heavy chain complementarity determining region 1 (CDRH1), CDRH2, and CDRH3, and wherein CDRH1, CDRH2, and CDRH3 comprise the sequence as set forth in SEQ ID NOs:3, 4, 5, respectively, with from 0 to 3 amino acid modifications; and (b) a light chain that comprises a light chain variable region (LCVR), wherein the LCVR comprises light chain complementarity determining region 1 (CDRL1), CDRL2, and CDRL3, and wherein CDRL1, CDRL2, and CDRL3 comprise the sequence as set forth in SEQ ID NOs: 6, 7, 8, respectively, with from 0 to 3 amino acid modifications. In some embodiments, the HCVR comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 1. In some embodiments, the HCVR comprises an amino acid sequence having at least 95% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 1. In some embodiments, the HCVR comprises an amino acid sequence having at least 97% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 1. In some embodiments, the HCVR comprises an amino acid sequence having at least 98% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 1. In some embodiments, the HCVR comprises an amino acid sequence having at least 99% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 1. In some embodiments, the HCVR comprises an amino acid sequence having 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 1. In some embodiments, the LCVR comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 2. In some embodiments, the LCVR comprises an amino acid sequence having at least 95% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 2. In some embodiments, the LCVR comprises an amino acid sequence having at least 97% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 2. In some embodiments, the LCVR comprises an amino acid sequence having at least 98% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 2. In some embodiments, the LCVR comprises an amino acid sequence having at least 99% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 2. In some embodiments, the LCVR comprises an amino acid sequence having 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 2. In some embodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 1, with from 0 to 10 amino acid modifications, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid modifications. In some embodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 1, with from 0 to 9 amino acid modifications. In some embodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 1, with from 0 to 8 amino acid modifications. In some embodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 1, with from 0 to 7 amino acid modifications. In some embodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 1, with from 0 to 6 amino acid modifications. In someembodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 1, with from 0 to 5 amino acid modifications. In some embodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 1, with from 0 to 4 amino acid modifications. In some embodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 1, with from 0 to 3 amino acid modifications. In some embodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 1, with from 0 to 2 amino acid modifications. In some embodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 1, with from 0 to 1 amino acid modifications. In some embodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 1. In some embodiments, the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 2, with from 0 to 10 amino acid modifications, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid modifications. In some embodiments, the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 2, with from 0 to 9 amino acid modifications. In some embodiments, the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 2, with from 0 to 8 amino acid modifications. In some embodiments, the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 2, with from 0 to 7 amino acid modifications. In some embodiments, the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 2, with from 0 to 6 amino acid modifications. In some embodiments, the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 2, with from 0 to 5 amino acid modifications. In some embodiments, the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 2, with from 0 to 4 amino acid modifications. In some embodiments, the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 2, with from 0 to 3 amino acid modifications. In some embodiments, the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 2, with from 0 to 2 amino acid modifications. In some embodiments, the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 2, with from 0 to 1 amino acid modifications. In some embodiments, the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 2.

[0032] Disclosed herein is an antibody or antigen-binding fragment thereof comprising (a) a heavy chain that comprises a heavy chain variable region (HCVR), wherein the HCVR comprises heavy chain complementarity determining region 1 (CDRH1), CDRH2, and CDRH3, and wherein CDRH1, CDRH2, and CDRH3 comprise the sequence as set forth in SEQ ID NOs: 11, 12, or 13, respectively, with from 0 to 3 amino acid modifications; and (b) a light chain that comprises a light chain variable region (LCVR), wherein the LCVR comprises light chain complementarity determining region 1 (CDRL1), CDRL2, and CDRL3, and wherein CDRL1, CDRL2, and CDRL3 comprise the sequence as set forth in SEQ ID NOs: 14, 15, or 16, respectively, with from 0 to 3 amino acid modifications. In some embodiments, the HCVRcomprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 9. In some embodiments, the HCVR comprises an amino acid sequence having at least 95% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 9. In some embodiments, the HCVR comprises an amino acid sequence having at least 97% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 9. In some embodiments, the HCVR comprises an amino acid sequence having at least 98% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 9. In some embodiments, the HCVR comprises an amino acid sequence having at least 99% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 9. In some embodiments, the HCVR comprises an amino acid sequence having 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 9. In some embodiments, the LCVR comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 10. In some embodiments, the LCVR comprises an amino acid sequence having at least 95% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 10. In some embodiments, the LCVR comprises an amino acid sequence having at least 97% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 10. In some embodiments, the LCVR comprises an amino acid sequence having at least 98% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 10. In some embodiments, the LCVR comprises an amino acid sequence having at least 99% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 10. In some embodiments, the LCVR comprises an amino acid sequence having 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 10. In some embodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 9, with from 0 to 10 amino acid modifications, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid modifications. In some embodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 9, with from 0 to 9 amino acid modifications. In some embodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 9, with from 0 to 8 amino acid modifications. In some embodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 9, with from 0 to 7 amino acid modifications. In some embodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 9, with from 0 to 6 amino acid modifications. In some embodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 9, with from 0 to 5 amino acid modifications. In some embodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 9, with from 0 to 4 amino acid modifications. In some embodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 9, with from 0 to 3 amino acid modifications. In some embodiments, the HCVR comprises an aminoacid sequence as set forth in SEQ ID NO: 9, with from 0 to 2 amino acid modifications. In some embodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 9, with from 0 to 1 amino acid modifications. In some embodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 9. In some embodiments, the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 10, with from 0 to 10 amino acid modifications, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid modifications. In some embodiments, the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 10, with from 0 to 9 amino acid modifications. In some embodiments, the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 10, with from 0 to 8 amino acid modifications. In some embodiments, the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 10, with from 0 to 7 amino acid modifications. In some embodiments, the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 10, with from 0 to 6 amino acid modifications. In some embodiments, the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 10, with from 0 to 5 amino acid modifications. In some embodiments, the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 10, with from 0 to 4 amino acid modifications. In some embodiments, the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 10, with from 0 to 3 amino acid modifications. In some embodiments, the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 10, with from 0 to 2 amino acid modifications. In some embodiments, the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 10, with from 0 to 1 amino acid modifications. In some embodiments, the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 10.

[0033] Disclosed herein is an antibody or antigen-binding fragment thereof comprising (a) a heavy chain that comprises a heavy chain variable region (HCVR), wherein the HCVR comprises heavy chain complementarity determining region 1 (CDRH1), CDRH2, and CDRH3, and wherein CDRH1, CDRH2, and CDRH3 comprise the sequence as set forth in SEQ ID NOs: 19, 20, or 21, respectively, with from 0 to 3 amino acid modifications; and (b) a light chain that comprises a light chain variable region (LCVR), wherein the LCVR comprises light chain complementarity determining region 1 (CDRL1), CDRL2, and CDRL3, and wherein CDRL1, CDRL2, and CDRL3 comprise the sequence as set forth in SEQ ID NOs: 22, 23, or 24, respectively, with from 0 to 3 amino acid modifications. In some embodiments, the HCVR comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 17. In some embodiments, the HCVR comprises an amino acid sequence having at least 95% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 17. In some embodiments, the HCVR comprises an amino acid sequence having at least 97% sequence identity to the aminoacid sequence as set forth in SEQ ID NO: 17. In some embodiments, the HCVR comprises an amino acid sequence having at least 98% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 17. In some embodiments, the HCVR comprises an amino acid sequence having at least 99% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 17. In some embodiments, the HCVR comprises an amino acid sequence having 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 17. In some embodiments, the LCVR comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 18. In some embodiments, the LCVR comprises an amino acid sequence having at least 95% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 18. In some embodiments, the LCVR comprises an amino acid sequence having at least 97% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 18. In some embodiments, the LCVR comprises an amino acid sequence having at least 98% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 18. In some embodiments, the LCVR comprises an amino acid sequence having at least 99% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 18. In some embodiments, the LCVR comprises an amino acid sequence having 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 18. In some embodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 17, with from 0 to 10 amino acid modifications, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid modifications. In some embodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 17, with from 0 to 9 amino acid modifications. In some embodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 17, with from 0 to 8 amino acid modifications. In some embodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 17, with from 0 to 7 amino acid modifications. In some embodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 17, with from 0 to 6 amino acid modifications. In some embodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 17, with from 0 to 5 amino acid modifications. In some embodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 17, with from 0 to 4 amino acid modifications. In some embodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 17, with from 0 to 3 amino acid modifications. In some embodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 17, with from 0 to 2 amino acid modifications. In some embodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 17, with from 0 to 1 amino acid modifications. In some embodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 17. In some embodiments, the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 18, with from 0 to 10 amino acid modifications,such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid modifications. In some embodiments, the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 18, with from 0 to 9 amino acid modifications. In some embodiments, the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 18, with from 0 to 8 amino acid modifications. In some embodiments, the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 18, with from 0 to 7 amino acid modifications. In some embodiments, the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 18, with from 0 to 6 amino acid modifications. In some embodiments, the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 18, with from 0 to 5 amino acid modifications. In some embodiments, the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 18, with from 0 to 4 amino acid modifications. In some embodiments, the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 18, with from 0 to 3 amino acid modifications. In some embodiments, the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 18, with from 0 to 2 amino acid modifications. In some embodiments, the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 18, with from 0 to 1 amino acid modifications. In some embodiments, the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 18.

[0034] Disclosed herein is an antibody or antigen-binding fragment thereof comprising (a) a heavy chain that comprises a heavy chain variable region (HCVR), wherein the HCVR comprises heavy chain complementarity determining region 1 (CDRH1), CDRH2, and CDRH3, and wherein CDRH1, CDRH2, and CDRH3 comprise the sequence as set forth in SEQ ID NOs: 27, 28, or 29, respectively, with from 0 to 3 amino acid modifications; and (b) a light chain that comprises a light chain variable region (LCVR), wherein the LCVR comprises light chain complementarity determining region 1 (CDRL1), CDRL2, and CDRL3, and wherein CDRL1, CDRL2, and CDRL3 comprise the sequence as set forth in SEQ ID NOs: 30, 31, or 32, respectively, with from 0 to 3 amino acid modifications. In some embodiments, the HCVR comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 25. In some embodiments, the HCVR comprises an amino acid sequence having at least 95% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 25. In some embodiments, the HCVR comprises an amino acid sequence having at least 97% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 25. In some embodiments, the HCVR comprises an amino acid sequence having at least 98% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 25. In some embodiments, the HCVR comprises an amino acid sequence having at least 99% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 25. In some embodiments, the HCVR comprises an amino acid sequence having 100% sequenceidentity to the amino acid sequence as set forth in SEQ ID NO: 25. In some embodiments, the LCVR comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 26. In some embodiments, the LCVR comprises an amino acid sequence having at least 95% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 26. In some embodiments, the LCVR comprises an amino acid sequence having at least 97% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 26. In some embodiments, the LCVR comprises an amino acid sequence having at least 98% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 26. In some embodiments, the LCVR comprises an amino acid sequence having at least 99% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 26. In some embodiments, the LCVR comprises an amino acid sequence having 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 26. In some embodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 25, with from 0 to 10 amino acid modifications, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid modifications. In some embodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 25, with from 0 to 9 amino acid modifications. In some embodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 25, with from 0 to 8 amino acid modifications. In some embodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 25, with from 0 to 7 amino acid modifications. In some embodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 25, with from 0 to 6 amino acid modifications. In some embodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 25, with from 0 to 5 amino acid modifications. In some embodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 25, with from 0 to 4 amino acid modifications. In some embodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 25, with from 0 to 3 amino acid modifications. In some embodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 25, with from 0 to 2 amino acid modifications. In some embodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 25, with from 0 to 1 amino acid modifications. In some embodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 25. In some embodiments, the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 26, with from 0 to 10 amino acid modifications, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid modifications. In some embodiments, the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 26, with from 0 to 9 amino acid modifications. In some embodiments, the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 26, with from 0 to 8 amino acid modifications. In some embodiments, the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 26, with from 0 to 7 amino acidmodifications. In some embodiments, the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 26, with from 0 to 6 amino acid modifications. In some embodiments, the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 26, with from 0 to 5 amino acid modifications. In some embodiments, the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 26, with from 0 to 4 amino acid modifications. In some embodiments, the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 26, with from 0 to 3 amino acid modifications. In some embodiments, the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 26, with from 0 to 2 amino acid modifications. In some embodiments, the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 26, with from 0 to 1 amino acid modifications. In some embodiments, the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 26.

[0035] Disclosed herein is an antibody or antigen-binding fragment thereof comprising (a) a heavy chain that comprises a heavy chain variable region (HCVR), wherein the HCVR comprises heavy chain complementarity determining region 1 (CDRH1), CDRH2, and CDRH3, and wherein CDRH1, CDRH2, and CDRH3 comprise the sequence as set forth in SEQ ID NOs: 35, 36, or 37, respectively, with from 0 to 3 amino acid modifications; and (b) a light chain that comprises a light chain variable region (LCVR), wherein the LCVR comprises light chain complementarity determining region 1 (CDRL1), CDRL2, and CDRL3, and wherein CDRL1, CDRL2, and CDRL3 comprise the sequence as set forth in SEQ ID NOs: 38, 39, or 40, respectively, with from 0 to 3 amino acid modifications. In some embodiments, the HCVR comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 33. In some embodiments, the HCVR comprises an amino acid sequence having at least 95% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 33. In some embodiments, the HCVR comprises an amino acid sequence having at least 97% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 33. In some embodiments, the HCVR comprises an amino acid sequence having at least 98% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 33. In some embodiments, the HCVR comprises an amino acid sequence having at least 99% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 33. In some embodiments, the HCVR comprises an amino acid sequence having 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 33. In some embodiments, the LCVR comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 34. In some embodiments, the LCVR comprises an amino acid sequence having at least 95% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 34. In some embodiments, theLCVR comprises an amino acid sequence having at least 97% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 34. In some embodiments, the LCVR comprises an amino acid sequence having at least 98% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 34. In some embodiments, the LCVR comprises an amino acid sequence having at least 99% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 34. In some embodiments, the LCVR comprises an amino acid sequence having 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 34. In some embodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 33, with from 0 to 10 amino acid modifications, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid modifications. In some embodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 33, with from 0 to 9 amino acid modifications. In some embodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 33, with from 0 to 8 amino acid modifications. In some embodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 33, with from 0 to 7 amino acid modifications. In some embodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 33, with from 0 to 6 amino acid modifications. In some embodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 33, with from 0 to 5 amino acid modifications. In some embodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 33, with from 0 to 4 amino acid modifications. In some embodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 33, with from 0 to 3 amino acid modifications. In some embodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 33, with from 0 to 2 amino acid modifications. In some embodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 33, with from 0 to 1 amino acid modifications. In some embodiments, the HCVR comprises an amino acid sequence as set forth in SEQ ID NO: 33. In some embodiments, the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 34, with from 0 to 10 amino acid modifications, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid modifications. In some embodiments, the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 34, with from 0 to 9 amino acid modifications. In some embodiments, the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 34, with from 0 to 8 amino acid modifications. In some embodiments, the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 34, with from 0 to 7 amino acid modifications. In some embodiments, the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 34, with from 0 to 6 amino acid modifications. In some embodiments, the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 34, with from 0 to 5 amino acid modifications. In some embodiments, the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 34, with from 0 to 4 amino acid modifications. In some embodiments, the LCVRcomprises an amino acid sequence as set forth in SEQ ID NO: 34, with from 0 to 3 amino acid modifications. In some embodiments, the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 34, with from 0 to 2 amino acid modifications. In some embodiments, the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 34, with from 0 to 1 amino acid modifications. In some embodiments, the LCVR comprises an amino acid sequence as set forth in SEQ ID NO: 34.

[0036] In some embodiments, the LCVR is linked to a light chain constant region comprising an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 62. In some embodiments, the LCVR is linked to a light chain constant region comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 62. In some embodiments, the LCVR is linked to a light chain constant region comprising an amino acid sequence having at least 97% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 62. In some embodiments, the LCVR is linked to a light chain constant region comprising an amino acid sequence having at least 98% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 62. In some embodiments, the LCVR is linked to a light chain constant region comprising an amino acid sequence having at least 99% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 62. In some embodiments, the LCVR is linked to a light chain constant region comprising an amino acid sequence having 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 62.

[0037] In some embodiments, the light chain variable region is linked to a light chain constant region comprising an amino acid sequence as set forth in SEQ ID NO: 62, with from 0 to 10 amino acid modifications, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid modifications. In some embodiments, the light chain variable region is linked to a light chain constant region comprising an amino acid sequence as set forth in SEQ ID NO: 62, with from 0 to 9 amino acid modifications. In some embodiments, the light chain variable region is linked to a light chain constant region comprising an amino acid sequence as set forth in SEQ ID NO: 62, with from 0 to 8 amino acid modifications. In some embodiments, the light chain variable region is linked to a light chain constant region comprising an amino acid sequence as set forth in SEQ ID NO: 62, with from 0 to 7 amino acid modifications. In some embodiments, the light chain variable region is linked to a light chain constant region comprising an amino acid sequence as set forth in SEQ ID NO: 62, with from 0 to 6 amino acid modifications. In some embodiments, the light chain variable region is linked to a light chain constant region comprising an amino acid sequence as set forth in SEQ ID NO: 62, with from 0 to 5 amino acid modifications. In some embodiments,the light chain variable region is linked to a light chain constant region comprising an amino acid sequence as set forth in SEQ ID NO: 62, with from 0 to 4 amino acid modifications. In some embodiments, the light chain variable region is linked to a light chain constant region comprising an amino acid sequence as set forth in SEQ ID NO: 62, with from 0 to 3 amino acid modifications. In some embodiments, the light chain variable region is linked to a light chain constant region comprising an amino acid sequence as set forth in SEQ ID NO: 62, with from 0 to 2 amino acid modifications. In some embodiments, the light chain variable region is linked to a light chain constant region comprising an amino acid sequence as set forth in SEQ ID NO: 62, with from 0 to 1 amino acid modifications. In some embodiments, the light chain variable region is linked to a light chain constant region comprising an amino acid sequence as set forth in SEQ ID NO: 62.

[0038] In some embodiments, the light chain variable region is linked to a light chain constant region comprising an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 64. In some embodiments, the light chain variable region is linked to a light chain constant region comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 64. In some embodiments, the light chain variable region is linked to a light chain constant region comprising an amino acid sequence having at least 97% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 64. In some embodiments, the light chain variable region is linked to a light chain constant region comprising an amino acid sequence having at least 98% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 64. In some embodiments, the light chain variable region is linked to a light chain constant region comprising an amino acid sequence having at least 99% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 64. In some embodiments, the light chain variable region is linked to a light chain constant region comprising an amino acid sequence having 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 64.

[0039] In some embodiments, the light chain variable region is linked to a light chain constant region comprising an amino acid sequence as set forth in SEQ ID NO: 64, with from 0 to 10 amino acid modifications, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid modifications. In some embodiments, the light chain variable region is linked to a light chain constant region comprising an amino acid sequence as set forth in SEQ ID NO: 64, with from 0 to 9 amino acid modifications. In some embodiments, the light chain variable region is linked to a light chain constant region comprising an amino acid sequence as set forth in SEQ ID NO: 64, with from 0 to 8 amino acid modifications. In some embodiments, the light chain variable region is linked to a light chain constant region comprising an amino acid sequence as set forth in SEQ ID NO: 64,with from 0 to 7 amino acid modifications. In some embodiments, the light chain variable region is linked to a light chain constant region comprising an amino acid sequence as set forth in SEQ ID NO: 64, with from 0 to 6amino acid modifications. In some embodiments, the light chain variable region is linked to a light chain constant region comprising an amino acid sequence as set forth in SEQ ID NO: 64, with from 0 to 5 amino acid modifications. In some embodiments, the light chain variable region is linked to a light chain constant region comprising an amino acid sequence as set forth in SEQ ID NO: 64, with from 0 to 4 amino acid modifications. In some embodiments, the light chain variable region is linked to a light chain constant region comprising an amino acid sequence as set forth in SEQ ID NO: 64, with from 0 to 3 amino acid modifications. In some embodiments, the light chain variable region is linked to a light chain constant region comprising an amino acid sequence as set forth in SEQ ID NO: 64, with from 0 to 2 amino acid modifications. In some embodiments, the light chain variable region is linked to a light chain constant region comprising an amino acid sequence as set forth in SEQ ID NO: 64, with from 0 to 1 amino acid modifications. In some embodiments, the light chain variable region is linked to a light chain constant region comprising an amino acid sequence as set forth in SEQ ID NO: 64.

[0040] In some embodiments, the heavy chain constant region comprises an amino acid sequence having at least 90% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 61. In some embodiments, the heavy chain constant region comprises an amino acid sequence having at least 95% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 61. In some embodiments, the heavy chain constant region comprises an amino acid sequence having at least 97% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 61. In some embodiments, the heavy chain constant region comprises an amino acid sequence having at least 98% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 61. In some embodiments, the heavy chain constant region comprises an amino acid sequence having at least 99% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 61. In some embodiments, the heavy chain constant region comprises an amino acid sequence having 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 61. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence as set forth in SEQ ID NO: 61, with from 0 to 10 amino acid modifications, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid modifications. In some embodiments, the heavy chain constant region comprises an amino acid sequence as set forth in SEQ ID NO: 61, with from 0 to 9 amino acid modifications. In some embodiments, the heavy chain constant region comprises an amino acid sequence as set forth in SEQ ID NO: 61, with from 0 to 8 amino acid modifications. In some embodiments, the heavy chain constant region comprises an amino acidsequence as set forth in SEQ ID NO: 61, with from 0 to 7 amino acid modifications. In some embodiments, the heavy chain constant region comprises an amino acid sequence as set forth in SEQ ID NO: 61, with from 0 to 6 amino acid modifications. In some embodiments, the heavy chain constant region comprises an amino acid sequence as set forth in SEQ ID NO: 61, with from 0 to 5 amino acid modifications. In some embodiments, the heavy chain constant region comprises an amino acid sequence as set forth in SEQ ID NO: 61, with from 0 to 4 amino acid modifications. In some embodiments, the heavy chain constant region comprises an amino acid sequence as set forth in SEQ ID NO: 61, with from 0 to 3 amino acid modifications. In some embodiments, the heavy chain constant region comprises an amino acid sequence as set forth in SEQ ID NO: 61, with from 0 to 2 amino acid modifications. In some embodiments, the heavy chain constant region comprises an amino acid sequence as set forth in SEQ ID NO: 61, with from 0 to 1 amino acid modifications. In some embodiments, the heavy chain constant region comprises an amino acid sequence as set forth in SEQ ID NO: 61.

[0041] In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 63. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 63. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence having at least 97% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 63. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence having at least 98% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 63. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence having at least 99% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 63. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence having 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 63. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence as set forth in SEQ ID NO: 63, with from 0 to 10 amino acid modifications, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid modifications. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence as set forth in SEQ ID NO: 63, with from 0 to 9 amino acid modifications. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence as set forth in SEQ ID NO: 63, with from 0 to 8 amino acid modifications. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence as set forth in SEQID NO: 63, with from 0 to 7 amino acid modifications. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence as set forth in SEQ ID NO: 63, with from 0 to 6 amino acid modifications. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence as set forth in SEQ ID NO: 63, with from 0 to 5 amino acid modifications. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence as set forth in SEQ ID NO: 63, with from 0 to 4 amino acid modifications. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence as set forth in SEQ ID NO: 63, with from 0 to 3 amino acid modifications. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence as set forth in SEQ ID NO: 63, with from 0 to 2 amino acid modifications. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence as set forth in SEQ ID NO: 63, with from 0 to 1 amino acid modifications. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence as set forth in SEQ ID NO: 63.

[0042] In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 75. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 75. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence having at least 97% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 75. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence having at least 98% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 75. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence having at least 99% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 75. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence having 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 75. In some embodiments, the heavy chain constant region comprises an amino acid sequence as set forth in SEQ ID NO: 75, with from 0 to 10 amino acid modifications, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid modifications. In some embodiments, the heavy chain constant region comprises an amino acid sequence as set forth in SEQ ID NO: 75, with from 0 to 9 amino acid modifications. In some embodiments, the heavy chain constant region comprises an amino acid sequence as set forth in SEQ ID NO: 75, with from 0 to 8 amino acid modifications. In someembodiments, the heavy chain constant region comprises an amino acid sequence as set forth in SEQ ID NO: 75, with from 0 to 7 amino acid modifications. In some embodiments, the heavy chain constant region comprises an amino acid sequence as set forth in SEQ ID NO: 75, with from 0 to 6 amino acid modifications. In some embodiments, the heavy chain constant region comprises an amino acid sequence as set forth in SEQ ID NO: 75, with from 0 to 5 amino acid modifications. In some embodiments, the heavy chain constant region comprises an amino acid sequence as set forth in SEQ ID NO: 75, with from 0 to 4 amino acid modifications. In some embodiments, the heavy chain constant region comprises an amino acid sequence as set forth in SEQ ID NO: 75, with from 0 to 3 amino acid modifications. In some embodiments, the heavy chain constant region comprises an amino acid sequence as set forth in SEQ ID NO: 75, with from 0 to 2 amino acid modifications. In some embodiments, the heavy chain constant region comprises an amino acid sequence as set forth in SEQ ID NO: 75, with from 0 to 1 amino acid modifications. In some embodiments, the heavy chain constant region comprises an amino acid sequence as set forth in SEQ ID NO: 75.

[0043] In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 76. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 76. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence having at least 97% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 76. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence having at least 98% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 76. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence having at least 99% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 76. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence having 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 76. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence as set forth in SEQ ID NO: 76, with from 0 to 10 amino acid modifications, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid modifications. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence as set forth in SEQ ID NO: 76, with from 0 to 9 amino acid modifications. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence as set forth in SEQ ID NO: 76, with from 0 to 8 amino acid modifications. In some embodiments, the HCVR islinked to a heavy chain constant region comprising an amino acid sequence as set forth in SEQ ID NO: 76, with from 0 to 7 amino acid modifications. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence as set forth in SEQ ID NO: 76, with from 0 to 6 amino acid modifications. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence as set forth in SEQ ID NO: 76, with from 0 to 5 amino acid modifications. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence as set forth in SEQ ID NO: 76, with from 0 to 4 amino acid modifications. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence as set forth in SEQ ID NO: 76, with from 0 to 3 amino acid modifications. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence as set forth in SEQ ID NO: 76, with from 0 to 2 amino acid modifications. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence as set forth in SEQ ID NO: 76, with from 0 to 1 amino acid modifications. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence as set forth in SEQ ID NO: 76.

[0044] In some embodiments, the HCVR is linked to a heavy chain constant region, wherein the heavy chain constant region comprises an Fc region that comprises one or more of the following amino acids: alanine (A) at position 234, alanine (A) at position 235, aspartic acid (D) at position 236, aspartic acid (D) at position 237, aspartic acid (D) at position 238, alanine (A) at position 265, glutamic acid (E) at position 267, glycine (G) at position 271, arginine (R) at position 330, alanine (A) at position 332, or alanine (A) at position 297 (numbering according to EU Index). In some embodiments, the Fc region comprises an aspartic acid (D) at position 238 (EU Index).

[0045] In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 77. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 77. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence having at least 97% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 77. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence having at least 98% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 77. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence having at least 99%sequence identity to the amino acid sequence as set forth in SEQ ID NO: 77. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence having 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 77. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence as set forth in SEQ ID NO: 77, with from 0 to 10 amino acid modifications, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid modifications. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence as set forth in SEQ ID NO: 77, with from 0 to 9 amino acid modifications. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence as set forth in SEQ ID NO: 77, with from 0 to 8 amino acid modifications. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence as set forth in SEQ ID NO: 77, with from 0 to 7 amino acid modifications. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence as set forth in SEQ ID NO: 77, with from 0 to 6 amino acid modifications. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence as set forth in SEQ ID NO: 77, with from 0 to 5 amino acid modifications. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence as set forth in SEQ ID NO: 77, with from 0 to 4 amino acid modifications. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence as set forth in SEQ ID NO: 77, with from 0 to 3 amino acid modifications. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence as set forth in SEQ ID NO: 77, with from 0 to 2 amino acid modifications. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence as set forth in SEQ ID NO: 77, with from 0 to 1 amino acid modifications. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence as set forth in SEQ ID NO: 77. In some embodiments, X at position 121 of SEQ ID NO: 77 is D. In some embodiments, X at position 121 of SEQ ID NO: 77 is P. In some embodiments, X at position 329 of SEQ ID NO: 77 is G. In some embodiments, X at position 329 of SEQ ID NO: 77 is absent. In some embodiments, X at position 330 of SEQ ID NO: 77 is K. In some embodiments, X at position 330 of SEQ ID NO: 77 is absent.

[0046] In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 78. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence as set forth in SEQID NO: 78. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence having at least 97% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 78. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence having at least 98% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 78. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence having at least 99% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 78. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence having 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 78. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence as set forth in SEQ ID NO: 78, with from 0 to 10 amino acid modifications, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid modifications. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence as set forth in SEQ ID NO: 78, with from 0 to 9 amino acid modifications. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence as set forth in SEQ ID NO: 78, with from 0 to 8 amino acid modifications. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence as set forth in SEQ ID NO: 78, with from 0 to 7 amino acid modifications. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence as set forth in SEQ ID NO: 78, with from 0 to 6 amino acid modifications. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence as set forth in SEQ ID NO: 78, with from 0 to 5 amino acid modifications. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence as set forth in SEQ ID NO: 78, with from 0 to 4 amino acid modifications. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence as set forth in SEQ ID NO: 78, with from 0 to 3 amino acid modifications. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence as set forth in SEQ ID NO: 78, with from 0 to 2 amino acid modifications. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence as set forth in SEQ ID NO: 78, with from 0 to 1 amino acid modifications. In some embodiments, the HCVR is linked to a heavy chain constant region comprising an amino acid sequence as set forth in SEQ ID NO: 78. In some embodiments, X at position 108 of SEQ ID NO: 78 is S. In some embodiments, X at position 108 of SEQ ID NO: 78 is P. In some embodiments, X at position 326 of SEQ ID NO: 78 is G. In some embodiments, X at position 326 of SEQ ID NO: 78 is absent. Insome embodiments, X at position 327 of SEQ ID NO: 78 is K. In some embodiments, X at position 327 of SEQ ID NO: 78 is absent.

[0047] In some cases, the antibody or antigen-binding fragment thereof binds a region at or in proximity of C-terminus of the extracellular portion of CD200R.

[0048] In some cases, the antibody or antigen-binding fragment thereof binds a region at most 50 amino acids, 45 amino acids, 40 amino acids, 35 amino acids, 30 amino acids, 25 amino acids, 20 amino acids, or 15 amino acids from the C-terminus of the extracellular portion of CD200R.

[0049] In some cases, the antibody or antigen-binding fragment thereof binds a region about 50 amino acids, 45 amino acids, 40 amino acids, 35 amino acids, 30 amino acids, 25 amino acids, 20 amino acids, 18 amino acids, 16 amino acids, 15 amino acids, 14 amino acids, 13 amino acids, 12 amino acids, 10 amino acids, 8 amino acids, 6 amino acids, or 5 amino acids from the C-terminus of the extracellular portion of CD200R.

[0050] In some cases, the antibody or antigen-binding fragment thereof binds a region at most 100 A, 90 A, 80 A, 70 A, 60 A, 50 A, 40 A, 30 A, 20 A, or 10 A from the cell membrane when the antibody or antigen-binding fragment thereof binds to a CD200R molecule on the cell membrane.

[0051] In some cases, the antibody or antigen-binding fragment thereof binds a region about 100 A, 90 A, 80 A, 70 A, 60 A, 50 A, 40 A, 30 A, 20 A, or 10 A from the cell membrane when the antibody or antigen-binding fragment thereof binds to a CD200R molecule on the cell membrane.

[0052] In some cases, the antibody or antigen-binding fragment thereof binds a region in proximity of N-terminus of CD200R.

[0053] In some cases, the antibody or antigen-binding fragment thereof binds a residue of CD200R selected from T213, E230, and S194.

[0054] In some cases, the antibody or antigen-binding fragment thereof binds a residue of CD200R selected from T213 and E230.

[0055] In some cases, the antibody or antigen-binding fragment thereof does not bind to cynomolgus CD200RLa, or binds to cynomolgus CD200RLa with a KD of more than 2 pM, as determined by surface plasmon resonance (SPR) at 37°C.

[0056] Disclosed herein, in some aspects, is an antibody or an antigen-binding fragment thereof of that specifically binds human CD200R or cynomolgus CD200R, wherein the antibody or antigen-binding fragment thereof does not bind to cynomolgus CD200RLa, or binds to cynomolgus CD200RLa with a KD of more than 2 pM, as determined by surface plasmon resonance (SPR) at 37°C.

[0057] Disclosed herein, in some aspects, is an antibody or an antigen-binding fragment thereof of that specifically binds CD200R, wherein the antibody or antigen-binding fragment thereof binds a region at or in proximity of C-terminus of the extracellular portion of CD200R.

[0058] In some cases, the antibody or antigen-binding fragment thereof binds a residue of CD200R selected from T213 and E230.

[0059] In some cases, the antibody or antigen-binding fragment thereof binds residues, T213 and E230, of CD200R.

[0060] In some cases, the antibody or antigen-binding fragment thereof is an IgG, an IgM, an IgE, an IgA, or an IgD molecule, or is derived from one of these.

[0061] In some cases, the antibody or antigen-binding fragment thereof is an IgGl, IgG2, IgG3, or IgG4 molecule, or is derived from one of these.

[0062] In some cases, the antibody is a monoclonal antibody.

[0063] In some cases, the antibody is a human or humanized antibody.

[0064] In some cases, the antibody is a chimeric antibody.

[0065] In some cases, the antigen-binding fragment thereof is selected from the group consisting of: scFv, sc(Fv)2, dsFv, Fab, Fab', (Fab')2 and a diabody.

[0066] In some cases, the antibody or antigen-binding fragment thereof comprises an Fc region.

[0067] In some cases, the Fc region comprises a modification.

[0068] In some cases, the antibody or antigen-binding fragment thereof possesses increased binding to FcyR2B compared to the parent molecule that lacks the Fc region modification.

[0069] In some cases, the antibody or antigen-binding fragment thereof possesses increased ratio of binding to FcyR2B / FcyR2A, compared to the parent molecule that lacks the Fc region modification.

[0070] In some cases, the Fc region comprises one or more of the following amino acids: alanine (A) at position 234, alanine (A) at position 235, aspartic acid (D) at position 236, aspartic acid (D) at position 237 aspartic acid (D) at position 238, alanine (A) at position 265, glutamic acid (E) at position 267, glycine (G) at position 271, arginine (R) at position 330, alanine (A) at position 332, and alanine (A) at position 297, all numbering according to EU Index.

[0071] In some cases, the heavy chain or light chain further comprise a constant region.

[0072] In some cases, the heavy chain and light chain are connected by a flexible linker to form a single-chain antibody.

[0073] In some cases, the antibody or antigen-binding fragment thereof agonizes CD200R expressed on the surface of an immune cell.

[0074] In some cases, when binding to CD200R of an immune cell, the antibody or antigen-binding fragment thereof reduces activation of the immune cell relative to a comparable immune cell not bound by the antibody or antigen-binding fragment thereof.

[0075] In some cases, when binding to CD200R of an immune cell, the antibody or antigen-binding fragment thereof decreases proliferation of the immune cell relative to a comparable immune cell not bound by the antibody or antigen-binding fragment thereof.

[0076] In some cases, the reduction in activation or proliferation of the immune cell is measured by an assay described in Example 5, 16, or 17.

[0077] In some cases, the decrease in cell proliferation or activation is measured in vitro or in vivo.

[0078] In some cases, the decrease in cell proliferation or activation is at least about 10%, 15%, 20%, 25%, 30%, 40%, or 50%.

[0079] In some cases, the decrease in cell proliferation or activation is from about 10% to 50%, 10% to 40%, 10% to 30%, 10% to 20%, 10% to 15%, 20% to 50%, 20% to 40%, or 20% to 30%.

[0080] In some cases, when binding to CD200R of an immune cell, the antibody or antigen-binding fragment thereof reduces expression of inflammatory genes in the immune cell relative to a comparable immune cell not bound by the antibody or antigen-binding fragment thereof.

[0081] In some cases, binding of the antibody or antigen-binding fragment thereof to CD200R expressed on the surface of an immune cell decreases NFKB signaling of the immune cell relative to a comparable immune cell not bound by the antibody or antigen-binding fragment thereof.

[0082] In some cases, the decrease in NFKB signaling of the immune cell is measured by an assay described in Example 5.

[0083] In some cases, the decrease in NFKB signaling of the immune cell is at least about 10%, 15%, 20%, 25%, 30%, or 40%.

[0084] In some cases, the decrease in NFKB signaling of the immune cell is from about 10% to 40%, 10% to 30%, 10% to 20%, 20% to 40%, or 30% to 40%.

[0085] In some cases, an average maximal percentage inhibition of NFKB signaling of the immune cell induced by the antibody or antigen-binding fragment thereof is at least 20%, 30%, 40%, 50%, or 60% greater than a control antibody that comprises: (a) a control heavy chain comprising CDRH1, CDRH2, and CDRH3, which comprise amino acid sequence as set forth inSEQ ID NOs: 55-57, respectively; and (b) a control light chain comprising CDRL1, CDRL2, and CDRL3, which comprise amino acid sequence as set forth in SEQ ID NOs: 58-60, respectively.

[0086] In some cases, an average maximal percentage inhibition of NFKB signaling of the immune cell induced by the antibody or antigen-binding fragment thereof is at least 20%, 30%, 40%, 50%, or 60% greater than a control antibody that comprises a control heavy chain variable region comprising amino acid sequence as set forth in SEQ ID NO: 53, and a control light chain variable region comprising amino acid sequence as set forth in SEQ ID NO: 54.

[0087] In some cases, the immune cell is a T cell or a monocyte.

[0088] In some cases, the antibody or antigen-binding fragment thereof inhibits activation of basophils.

[0089] In some cases, the antibody or antigen-binding fragment thereof inhibits activation of basophils induced by FcsRI.

[0090] In some cases, the antibody or antigen-binding fragment thereof inhibits activation of basophils induced by binding of IgE to the basophils.

[0091] In some cases, the antibody or antigen-binding fragment thereof inhibits activation of basophils by at least 40% or at least 50%.

[0092] In some cases, the antibody or antigen-binding fragment thereof inhibits activation of basophils by about 10% to about 90%, about 20% to about 70%, about 30% to about 60%, or about 40% to about 60%.

[0093] In some cases, the antibody or antigen-binding fragment thereof inhibits activation of basophils by about 10%, 20%, 30%, 40%, 45%, 50%, 55%, 60%, 70%, 80%, or 90%. In some cases, the inhibition of activation of basophils is measured in an assay described in Example 10.

[0094] In some cases, the antibody or antigen-binding fragment thereof does not inhibit binding of CD200 to CD200R.

[0095] In some cases, the antibody or antigen-binding fragment thereof binds human CD200R with a KD of less than 10 nM, as determined by surface plasmon resonance (SPR) at 37°C.

[0096] In some cases, the antibody or antigen-binding fragment thereof binds human CD200R with a KD of less than 5 nM, as determined by surface plasmon resonance (SPR) at 37°C.

[0097] In some cases, the antibody or antigen-binding fragment thereof binds human CD200R with a KD of less than 2 nM, as determined by surface plasmon resonance (SPR) at 37°C.

[0098] In some cases, the antibody or antigen-binding fragment thereof binds human CD200R with a KD of less than 1 nM, as determined by surface plasmon resonance (SPR) at 37°C.

[0099] In some cases, the antibody or antigen-binding fragment thereof binds human CD200R with a KD of less than 0.5 nM, as determined by surface plasmon resonance (SPR) at 37°C.[000100] In some cases, the antibody or antigen-binding fragment thereof binds cynomolgus CD200R with a KD of less than 100 nM, as determined by surface plasmon resonance (SPR) at 37°C.[000101] In some cases, the antibody or antigen-binding fragment thereof binds cynomolgus CD200R with a KD of less than 1 nM, as determined by surface plasmon resonance (SPR) at 37°C.[000102] In some cases, the antibody or antigen-binding fragment thereof binds cynomolgus CD200R with a KD of less than 0.1 nM, as determined by surface plasmon resonance (SPR) at 37°C.[000103] In some cases, the antibody or antigen-binding fragment thereof binds cynomolgus CD200R with a KD of less than 0.01 nM, as determined by surface plasmon resonance (SPR) at 37°C.[000104] In some cases, the antibody or antigen-binding fragment thereof does not induce significant cytokine release when the antibody or antigen-binding fragment thereof binds to CD200R on the surface of an immune cell.[000105] In some cases, the antibody or antigen-binding fragment thereof comprises a domain that binds to an Fc receptor.[000106] In some cases, the Fc receptor is expressed on the surface of an immune cell.[000107] In some cases, the immune cell is an antigen presenting cell.[000108] In some cases, the antigen presenting cell is a dendritic cell, macrophage, monocyte, or neutrophil.[000109] In some cases, the binding of the antibody or antigen-binding fragment thereof to the Fc receptor expressed on the surface of the immune cell and binding to CD200R on the surface of a second immune cell results in the cell surface of the immune cell and the cell surface of the second immune cell to be within 250A, 200A, 150A, or lOOA.[000110] In some cases, the binding of the antibody or antigen-binding fragment thereof to the Fc receptor expressed on the surface of the immune cell and binding to CD200R on the surface of a second immune cell results in the cell surface of the immune cell and the cell surface of the second immune cell to be within 250A, 200A, 150A, or lOOA.[000111] In some cases, the Fc receptor is FcyRIIB.[000112] In some cases, the antibody or antigen-binding fragment thereof is bi-specific or multi-specific.[000113] Disclosed herein, in some aspects, is an isolated nucleic acid that comprises one or more nucleotide sequences encoding polypeptides capable of forming the antibody or antigenbinding fragment thereof disclosed herein.[000114] Disclosed herein, in some aspects, is a vector that comprises one or more nucleotide sequences encoding polypeptides capable of forming the antibody or antigen-binding fragment thereof disclosed herein.[000115] Disclosed herein, in some aspects, is a host cell comprising one or more nucleic acid molecules encoding the amino acid sequence of a heavy chain and a light chain which when expressed are capable of forming the antibody or antigen-binding fragment thereof disclosed herein.[000116] Disclosed herein, in some aspects, is a method, comprising culturing the host cell disclosed herein under conditions for production of the antibody or antigen-binding fragment thereof.[000117] Disclosed herein, in some aspects, is a method, comprising:[000118] (a) providing a host cell comprising one or more nucleic acid molecules encoding the amino acid sequence of a heavy chain and a light chain which when expressed are capable of forming the antibody or antigen-binding fragment thereof disclosed herein;[000119] (b) culturing the host cell expressing the encoded amino acid sequence; and[000120] (c) isolating the antibody or the antigen-binding fragment thereof.[000121] Disclosed herein, in some aspects, is an immunoconjugate comprising the antibody or antigen-binding fragment thereof disclosed herein conjugated with an agent. [000122] Disclosed herein, in some aspects, is a pharmaceutical composition comprising a therapeutically effective amount of the antibody or antigen-binding fragment thereof disclosed herein or the immunoconjugate disclosed herein, and at least one pharmaceutically acceptable excipient.[000123] Disclosed herein, in some aspects, is an antibody or antigen-binding fragment thereof disclosed herein or the immunoconjugate disclosed herein or a pharmaceutical composition disclosed herein for use in therapy.[000124] Disclosed herein, in some aspects, is a kit comprising the antibody or antigenbinding fragment thereof disclosed herein, the immunoconjugate disclosed herein, or the pharmaceutical composition disclosed herein in a container.[000125] In some cases, the kit further comprises an informational material containing instructions for use of the antibody or antigen-binding fragment thereof disclosed herein, the immunoconjugate disclosed herein, or the pharmaceutical composition disclosed herein.[000126] Disclosed herein, in some aspects, is a method of treating a disease or condition in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the antibody or antigen-binding fragment thereof disclosed herein or the immunoconjugate disclosed herein, or administering to the subject the pharmaceutical composition disclosed herein.[000127] In some cases, the disease or condition comprises a disease or condition associated with CD200R.[000128] In some cases, the disease or condition comprises an autoimmune disease or condition or an inflammatory disease or condition.[000129] In some cases, the disease or condition comprises acute disseminated encephalomyelitis (ADEM), Addison's disease, allergy, alopecia areata, amyotrophic lateral sclerosis, ankylosing spondylitis, anti-phospholipid syndrome, asthma, autoimmune haemolytic anaemia, autoimmune hepatitis, autoimmune pancreatitis, autoimmune polyendocrine syndrome, Behcet’s disease, bullous pemphigoid, cerebral malaria, chronic inflammatory demyelinating polyneuropathy, coeliac disease, Crohn's disease, Cushing's Syndrome, dermatitis herpetiformis, dermatomyositis, diabetes mellitus type 1, eosinophilic granulomatosis with polyangiitis, gallbladder disease, graft versus host disease, Graves' disease, Guillain-Barre syndrome, Hashimoto’s thyroiditis, Hi dradenitis Suppurativa, inflammatory bowel disease (IBD), inflammatory fibrosis, irritable bowel syndrome, juvenile arthritis, Kawasaki disease, leukemia, lyme arthritis, lymphoma, lymphoproliferative disorders, meningoencephalitis, multiple sclerosis, myasthenia gravis, myeloma, neuromyelitis optica, pelvic inflammatory disease, pemphigus, peritonitis, Pilonidal disease, polymyositis, primary biliary cholangitis, primary sclerosing cholangitis, psoriasis, psoriatic arthritis, rheumatoid arthritis, sarcoidosis, Sjogren's syndrome, systemic lupus erythematosus, Takayasu’s arteritis, temporal arteritis, transplant rejection, transverse myelitis, ulcerative colitis, uveitis, vasculitis, vitiligo and Vogt-Koyanagi -Harada Disease.[000130] In some cases, the disease or condition comprises an autoimmune skin disease or condition.[000131] In some cases, the autoimmune skin disease or condition comprises Behcet’s disease, dermatitis herpetiformis, dermatomyositis, epidermolysis bullosa, lichen planus, linear IgA disease, lupus of the skin, morphea / scleroderma, ocular cicatrical pemphigoid, pemphigoid, bullous pemphigoid, pemphigus, psoriasis, scleroderma, or vasculitis.[000132] In some cases, the subject is a human subject.[000133] Disclosed herein, in some aspects, is a method of downregulating an immune response in a subject, comprising administering the subject the antibody or antigen-binding fragment thereof or the immunoconjugate disclosed herein, or administering to the subject the pharmaceutical composition disclosed herein.[000134] Disclosed herein, in some aspects, is a method of suppressing an immune cell that expresses CD200R, comprising contacting the immune cell with the antibody or antigen-binding fragment thereof disclosed herein or the immunoconjugate disclosed herein.[000135] In some cases, the immune cell comprises a T cell, a B cell, or a macrophage.[000136] In some cases, the immune cell comprises an antigen-specific T cell.[000137] In some cases, the subject is a human subject.INCORPORATION BY REFERENCE[000138] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.BRIEF DESCRIPTION OF THE DRAWINGS[000139] The novel features of the disclosure are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present disclosure will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the disclosure are utilized, and the accompanying drawings of which:[000140] FIGS. 1A-1B show surface plasmon resonance (SPR) curves that demonstrate binding of CD200 by CD200R that is injected over and captured by immobilized anti-CD200R antibody for a non-competing clone (FIG. 1A) and a competing clone (FIG. IB), respectively. For a non-competing clone (exemplified in FIG. 1A), CD200R captured by the non-competing CD200R antibodies can bind to its natural ligand CD200, thus showing an increase in SPR signal on the graph, while for a competing clone (exemplified in FIG. IB), CD200R captured by the competing CD200R antibodies cannot bind to its natural ligand CD200, thus no significant change in SPR signal on the graph.[000141] FIG. 2 shows the epitope map of clone 21.3.1 as defined by surface mutagenesis. The mutated surface residues that reduce binding of the antibody by >90% relative to wild type receptor are indicated by residue number (E230 and T213), while mutated surface residues thathave no effect on antibody binding are shaded but not indicated by residue number. The epitope was found to be near the C-terminus of CD200R very close to the likely position of the cell membrane. As shown, the orientation of the receptor with respect to the cell membrane is predicted by positioning the C-terminus of the extracellular portion in proximity to the membrane and the N-terminus distal to the membrane.[000142] FIG. 3 shows alignment of exemplary humanized VH and VL variants to the murine parental clone 21.3.1 variable domain sequences.[000143] FIGS. 4A-4D show predicted immunogenicity, based on HLA-DR binding scores, for the murine parental variable domains and exemplary humanized variable domains of clone 21.3.1.[000144] FIGS. 5A-5D demonstrate the inhibition of FcsRI-induced basophil activation. FIG. 5A is a schematic overview of the experiment. FIG. 5B show images of basophils from an individual donor 30 minutes after IgE stimulation. FIGS. 5C-5D show plots quantifying basophil activation, expressed as the count of CD63+ cells (light grey objects in FIG. 5B) divided by the total cell count (phase objects in FIG. 5B). Results for individual donors are plotted in FIG. 5C. Normalized AUCs were summarized in FIG. 5D.[000145] FIGS. 6A-6C illustrate gene pathways regulated by CD200R signaling. FIG. 6A shows results from RNA sequencing that confirmed the agonistic effect of an exemplary CD200R agonistic antibody according to some embodiments of the present disclosure, with the identification of 2080 differentially expressed genes (899 upregulated, 1181 downregulated) when comparing stimulated THP-1 cells in the presence of CD200R agonistic antibody vs isotype control. FIG. 6B shows gene set enrichment analysis, which revealed that CD200R agonism by the CD200R agonistic antibody downregulated key inflammatory pathways associated with chronic inflammatory conditions. FIG. 6C shows that CD200R1 is upregulated in skin biopsies from atopic dermatitis patients.[000146] FIG. 7 shows binding curves for CD200R antibodies, or relevant isotype controls, to human CD200R expressing Jurkat T cells, as assessed by flow cytometry.[000147] FIG. 8 shows the output of an enzyme fragment complementation assay which reports D0K2 recruitment to the cytoplasmic tail of CD200R in a Jurkat T cell line.DETAILED DESCRIPTION[000148] Disclosed herein, in some aspects, are methods, compositions, kits, vectors, polynucleotides, and host cells relating to an antibody recognizing immune cell receptor CD200R. In some embodiments, the antibody or antigen-binding fragment thereof is an agonistantibody. In some embodiments, the agonist antibody specifically binds to CD200R. In some embodiments, the agonist antibody specifically binds to human CD200R.[000149] In some embodiments, the agonist anti-CD200R antibody disclosed herein enhances or activates the CD200R signaling pathway. In some embodiments, the anti-CD200R antibody downregulates immune response. In some embodiments, the anti-CD200R antibody downregulates inflammation. In some embodiments, the anti-CD200R antibody downregulates NF-KB signaling. In some embodiments, the anti-CD200R antibody decreases immune cell proliferation relative to a comparable immune cell not bound by the anti-CD200R antibody. [000150] Without wishing to be bound by a certain theory, the anti-CD200R antibodies disclosed herein enhance CD200R signaling pathway by enhancing activation of CD200R or signaling pathway induced by activated CD200R, e.g., interaction of Dok2 with the membrane distal tyrosine residue located within a phosphotyrosine-binding (PTB) domain recognition motif (NPxY), phosphorylation of tyrosine residues of CD200R, and / or recruitment of SHIP and RasGAP. In some cases, the anti-CD200R antibodies bind CD200R on the surface of an immune cell. In some cases, the anti-CD200R antibodies bind another surface protein expressed on the surface of another immune cell. In some cases, anti-CD200R antibodies can bring the surfaces of the two immune cells into close proximity. In some embodiments, such close proximity is 250A, 200A, 150A, or lOOA. In some cases, close proximity of the two immune cells reduces bulky phosphatase(s) at or near the immune synapse between the two immune cells. In some embodiments, bulky phosphatase contributes to dephosphorylation of the CD200R. In some embodiments, decreased bulky phosphatase leads to more phosphorylation of CD200R, which in turn enhances the CD200R signaling pathway. In some embodiments, the immune cell is a T cell. In some cases, the immune cell is a monocyte.[000151] In some embodiments, the anti-CD200R antibody recognizes an extracellular region of human CD200R. In some embodiments, the antibody recognizes an extracellular region of cynomolgus CD200R. In some embodiments, the anti-CD200R antibody does not compete with CD200R’s natural ligand. In some cases, the antibody binds a region near the C-terminus of CD200R, or C-terminus of the extracellular portion of CD200R. In some cases, the anti- CD200R antibody binds a region close to the likely position of the cell membrane. In some cases, antibody binds a region close to the N-terminus of domain 2. When expressed on the surface of a cell membrane, CD200R can have extracellular portion, transmembrane portion, and intracellular portion. CD200R can have two IgSF domains in its extracellular portion when expressed on the surface of a cell membrane, domain 1 and domain 2, e.g., as described in Wright et al. J Immunol 2003; 171 :3034-3046, which is incorporated herein by reference in its entirety. Domain 1 is the N-terminal domain in the extracellular portion of CD200R and domain 2 is the C-terminaldomain in the extracellular portion of CD200R. CD200R domain 2 is the more membrane proximal domain.[000152] In other cases, the anti-CD200R antibody binds a region more distal from the cell membrane. In some embodiments, the anti-CD200R binds a T213 residue of CD200R. In some embodiments, the anti-CD200R binds a E230 residue of CD200R. In some embodiments, the anti-CD200R binds a T213 residue and a E230 residue of CD200R. In some embodiments, the anti-CD200R binds a S194 residue of CD200R.[000153] In some embodiments, the CD200R agonist antibodies disclosed are more efficacious than currently existing antibodies (e.g., I-4P described in Example 5) at promoting the CD200R inhibitory signaling toward immune cells and / or the immune system, downregulating immune cell responses. In some cases, the anti-CD200R antibodies disclosed herein enhance CD200R’s inhibition of the NF-KB pathway more effectively than currently existing antibodies (e.g., I-4P). The anti-CD200R antibodies disclosed herein can be particularly useful in the treatment of immune mediated, and / or CD200R associated disorders, or diseases generated by aberrant immune pathologies or having cancerous origins.[000154] In some embodiments, the antibody is a human antibody. In some embodiments, the CD200R antibody disclosed herein is a humanized antibody. In some embodiments, the CD200R agonist antibody is a monoclonal antibody. In some embodiments, the CD200R antibody is a chimeric antibody. In some embodiments, the CD200R antibody is generated in mice. In some embodiments, the CD200R antibody comprises one or more modifications in its Fc region. In some embodiments, the CD200R antibody comprises one or more modifications in its heavy chain. In some embodiments, the CD200R antibody comprises one or more modifications in its light chain.[000155] In some embodiments, the CD200R antibody is an IgG molecule or is derived from an IgG molecule. In some embodiments, the CD200R antibody is an IgM molecule or is derived from an IgM molecule. In some embodiments, the CD200R antibody is an IgE molecule or is derived from an IgE molecule. In some embodiments, the CD200R antibody is an IgA molecule or is derived from an IgA molecule. In some embodiments, the CD200R antibody is an IgD molecule or is derived from an IgD molecule.[000156] In some aspects, disclosed herein are compositions, systems, pharmaceutical compositions, method of treatments, kits, and methods of manufacturing that relate to CD200R antibodies.[000157] It is to be understood that one, some, or all of the properties of the various embodiments described herein may be applied to any aspect unless the content clearly dictates otherwise. Furthermore, that the various embodiments may be combined to form otherembodiments of the present disclosure. These and other aspects of the disclosure will become apparent to one of skill in the art. These and other embodiments of the disclosure are further described by the detailed description that follows.[000158] Definitions[000159] The terms “agonist,” “agonistic,” “agonize,” and other grammatically equivalents, as used herein, refer to or relate to an agent that can bind to a receptor or any other protein target, and activate or enhance an activity of, or help initiate activation of, the receptor or protein target. In some cases, an agonist can promote the receptor or other protein target that it binds to, to induce a biological response, e.g., signal transduction or other changes in cellular activities. As used herein, a CD200R agonist antibody (or antibody fragment) refers to an antibody (or antibody fragment) that binds to CD200R expressed on the surface of an immune cell and enhances its inhibitory signal to the immune cell, including without limitation T cells, macrophages and / or B lymphocytes.[000160] In the present disclosure, wherever aspects are described herein with the language "comprising," otherwise analogous aspects described in terms of "consisting of' and / or "consisting essentially of are also provided. All definitions herein described whether specifically mentioned or not, should be construed to refer to definitions as used throughout the specification and attached claims.[000161] Throughout the specification and attached claims, the singular form “a”, “an” and “the” include plural references unless the context clearly dictates otherwise. For example, the term “a cell” includes a plurality of cells, including mixtures thereof.[000162] In the present disclosure, one, some, or all of the properties of the various embodiments described herein may be applied to any aspect unless the content clearly dictates otherwise. Furthermore, that the various embodiments may be combined to form other embodiments of the present disclosure. These and other aspects of the disclosure will become apparent to one of skill in the art. These and other embodiments of the disclosure are further described by the detailed description herein.[000163] Throughout the specification and attached claims, and unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure is related. For example, the Concise Dictionary of Biomedicine and Molecular Biology, Juo, Pei-Show, 2nd ed., 2002, CRC Press; The Dictionary of Cell and Molecular Biology, 3rd ed., 1999, Academic Press; and the Oxford Dictionary Of Biochemistry And Molecular Biology, Revised, 2000, Oxford University Press, provide one of ordinary skill with a general dictionary of many of the terms used in this disclosure.[000164] Amino acids may be referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Nucleotides, likewise, may be referred to by their commonly accepted single- letter codes.[000165] The numbering of amino acids in the variable domain, CDRs and framework regions (FRs), of an antibody follow, unless otherwise indicated, the Kabat definition as set forth in Kabat et al. Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD. (1991).[000166] The term “about” or “approximately” means within an acceptable error range for the particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, i.e., the limitations of the measurement system. For example, “about” can mean within 1 or more than 1 standard deviation, per the practice in the art. Alternatively, “about” can mean a range of up to 20%, up to 10%, up to 5%, or up to 1% of a given value. Alternatively, particularly with respect to biological systems or processes, the term can mean within an order of magnitude, preferably within 5 -fold, and more preferably within 2- fold, of a value. Where particular values are described in the application and claims, unless otherwise stated the term “about” meaning within an acceptable error range for the particular value should be assumed.[000167] The terms “polypeptide”, “oligopeptide”, “peptide” and “protein” are used interchangeably herein to refer to polymers of amino acids of any length. The polymer may be linear or branched, it may comprise modified amino acids, and it may be interrupted by nonamino acids. The terms also encompass an amino acid polymer that has been modified naturally or by intervention; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation or modification, such as conjugation with a labeling component. Also included within the definition are, for example, polypeptides containing one or more analogs of an amino acid (including, for example, unnatural amino acids, etc.), as well as other modifications known in the art. It is understood that, because the polypeptides as described herein are based upon an antibody, the polypeptides can occur as single chains or associated chains.[000168] The term “amino acid” refers to natural, unnatural, and synthetic amino acids, including but not limited to both the D or L optical isomers, and amino acid analogs and peptidomimetics. Standard single or three letter codes are used to designate amino acids.[000169] A “variant” when applied to a protein is a protein with sequence homology to the native biologically active protein that retains at least a portion of the therapeutic and / or biological activity of the biologically active protein. For example, a variant protein may share at least 70%,75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% amino acid sequence identity compared with the reference biologically active protein or any ranges in between the at least 70% and 99%. As used herein, the term “biologically active protein moiety” includes proteins modified deliberately, as for example, by site directed mutagenesis, synthesis of the encoding gene, insertions, or accidentally through mutations.[000170] In the context of polypeptides, a “linear sequence” or a “sequence” is an order of amino acids in a polypeptide in an amino to carboxyl terminus direction in which residues that neighbor each other in the sequence are contiguous in the primary structure of the polypeptide. A “partial sequence” is a linear sequence of part of a polypeptide that is known to comprise additional residues in one or both directions.[000171] “Polynucleotide,” or “nucleic acid,” as used interchangeably herein, refer to polymers of nucleotides of any length, and include DNA and RNA. The nucleotides can be deoxyribonucleotides, ribonucleotides, modified nucleotides or bases, and / or their analogs, or any substrate that can be incorporated into a polymer by DNA or RNA polymerase. A polynucleotide may comprise modified nucleotides, such as methylated nucleotides and their analogs. If present, modification to the nucleotide structure may be imparted before or after assembly of the polymer. The sequence of nucleotides may be interrupted by non-nucleotide components. A polynucleotide may be further modified after polymerization, such as by conjugation with a labeling component. Other types of modifications include, for example, “caps”, substitution of one or more of the naturally occurring nucleotides with an analog, internucleotide modifications such as, for example, those with uncharged linkages (e.g., methyl phosphonates, phosphotriesters, phosphoamidates, carbamates, etc.) and with charged linkages (e.g., phosphorothioates, phosphorodithioates, etc.), those containing pendant moieties, such as, for example, proteins (e.g., nucleases, toxins, antibodies, signal peptides, ply-L-lysine, etc.), those with intercalators (e.g., acridine, psoralen, etc.), those containing chelators (e.g., metals, radioactive metals, boron, oxidative metals, etc.), those containing alkylators, those with modified linkages (e.g., alpha anomeric nucleic acids, etc.), as well as unmodified forms of the polynucleotide(s). Further, any of the hydroxyl groups ordinarily present in the sugars may be replaced, for example, by phosphonate groups, phosphate groups, protected by standard protecting groups, or activated to prepare additional linkages to additional nucleotides, or may be conjugated to solid supports. The 5’ and 3’ terminal OH can be phosphorylated or substituted with amines or organic capping group moieties of from 1 to 20 carbon atoms. Other hydroxyls may also be derivatized to standard protecting groups. Polynucleotides can also contain analogous forms of ribose or deoxyribose sugars that are generally known in the art, including, for example, 2’-O-methyl-, 2’-O-allyl, 2’ -fluoro- or 2’ -azido-ribose, carbocyclic sugar analogs,a-anomeric sugars, epimeric sugars such as arabinose, xyloses or lyxoses, pyranose sugars, furanose sugars, sedoheptuloses, acyclic analogs and abasic nucleoside analogs such as methyl riboside. One or more phosphodiester linkages may be replaced by alternative linking groups. These alternative linking groups include, but are not limited to, embodiments wherein phosphate is replaced by P(O)S(“thioate”), P(S)S (“dithioate”), (O)NR2(“amidate”), P(O)R, P(O)OR’, CO or CH2 (“formacetal”), in which each R or R’ is independently H or substituted or unsubstituted alkyl (1-20 C) optionally containing an ether (-O-) linkage, aryl, alkenyl, cycloalkyl, cycloalkenyl or araldyl. Not all linkages in a polynucleotide need be identical. The preceding description applies to all polynucleotides referred to herein, including RNA and DNA.[000172] A “variable region” of an antibody refers to the variable region of the antibody light chain or the variable region of the antibody heavy chain, either alone or in combination. The variable regions of the heavy and light chain each consist of four framework regions (FR) connected by three complementarity determining regions (CDRs) also known as hypervariable regions. The CDRs in each chain are held together in close proximity by the FRs and, with the CDRs from the other chain, contribute to the formation of the antigen-binding site of antibodies. There are at least two techniques for determining CDRs: (1) an approach based on cross-species sequence variability (i.e., Kabat et al. Sequences of Proteins of Immunological Interest, (5th ed., 1991, National Institutes of Health, Bethesda MD)); and (2) an approach based on crystallographic studies of antigen-antibody complexes (Al-lazikani et al (1997) J. Molec. Biol. 273 :927-948)). As used herein, a CDR may refer to CDRs defined by either approach or by a combination of both approaches.[000173] A “constant region” of an antibody refers to the constant region of the antibody light chain or the constant region of the antibody heavy chain, either alone or in combination. [000174] A “host cell” includes an individual cell or cell culture that can be or has been a recipient for vector(s) comprising exogenous polynucleotides. Host cells include progeny of a single host cell, and the progeny may not necessarily be completely identical (in morphology or in genomic DNA complement) to the original parent cell due to natural, accidental, or deliberate mutation. A host cell includes cells transfected in vivo with a polynucleotide(s) of the present disclosure.[000175] The term "Fc region" is used to define a C-terminal region of an immunoglobulin heavy chain. The "Fc region" may be a native sequence Fc region or a variant Fc region. Although the boundaries of the Fc region of an immunoglobulin heavy chain might vary, the human IgG heavy chain Fc region is usually defined to stretch from an amino acid residue at position Cys226, or from Pro230, to the carboxyl-terminus thereof. The numbering of the residues in the Fc region is that of the EU index as in Kabat. (Kabat et al., Sequences of Proteinsof Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md., 1991.) The Fc region of an immunoglobulin generally comprises two constant domains, CH2 and CH3.[000176] A “functional Fc region” possesses at least one effector function of a native sequence Fc region. Exemplary “effector functions” include Clq binding; complement dependent cytotoxicity (CDC); Fc receptor binding; antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; down-regulation of cell surface receptors (e.g., B cell receptor; BCR), etc. Such effector functions generally require the Fc region to be combined with a binding domain (e.g., an antibody variable domain) and can be assessed using various assays known in the art for evaluating such antibody effector functions.[000177] A “native sequence Fc region” comprises an amino acid sequence identical to the amino acid sequence of an Fc region found in nature. A “variant Fc region” comprises an amino acid sequence which differs from that of a native sequence Fc region by virtue of at least one amino acid modification yet retains at least one effector function of the native sequence Fc region. Preferably, the variant Fc region has at least one amino acid substitution compared to a native sequence Fc region or to the Fc region of a parent polypeptide, e.g., from about one to about ten amino acid substitutions, and preferably from about one to about five amino acid substitutions in a native sequence Fc region or in the Fc region of the parent polypeptide. The variant Fc region herein will preferably possess at least about 80% sequence identity with a native sequence Fc region and / or with an Fc region of a parent polypeptide, and most preferably at least about 90% sequence identity therewith, more preferably at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99% sequence identity and sequence identity between said ranges therewith.[000178] An “individual” or a "subject" is a mammal, more preferably a human. Mammals also include, but are not limited to, farm animals, sport animals, pets, primates, horses, dogs, cats, mice and rats.[000179] As used herein, "vector" means a construct, which is capable of delivering, and preferably expressing, one or more gene(s) or sequence(s) of interest in a host cell. Examples of vectors include, but are not limited to, viral vectors, naked DNA or RNA expression vectors, plasmid, cosmid or phage vectors, DNA or RNA expression vectors associated with cationic condensing agents, DNA or RNA expression vectors encapsulated in liposomes, and certain eukaryotic cells, such as producer cells.[000180] The term “effective amount” or “therapeutically effective amount” refers to the amount of an agent that is sufficient to effect beneficial or desired results. The therapeutically effective amount may vary depending upon one or more of: the subject and disease conditionbeing treated, the weight and age of the subject, the severity of the disease condition, the manner of administration and the like, which can readily be determined by one of ordinary skill in the art. The term “effective amount” also applies to a dose that will provide an image for detection by an appropriate imaging method. The specific dose may vary depending on one or more of: the particular agent chosen, the dosing regimen to be followed, whether it is administered in combination with other compounds, timing of administration, the tissue to be imaged, and the physical delivery system in which it is carried. An effective amount of an active agent may be administered in a single dose or in multiple doses. A therapeutically effective amount of antibody ranges from about 0.001 to about 25 mg / kg body weight, preferably from about 0.01 to about 25 mg / kg body weight, from about 0.1 to about 20 mg / kg body weight, or from about 1 to about 10 mg / kg. The dosage may be adjusted, as necessary, to suit observed effects of the treatment and / or as most effective to provide a cure, prevention, control symptoms and the like as determined by one of ordinary skills in the art. The appropriate dose is chosen based on clinical indications by a treating physician or person of skill in the art. A component may be described herein as having at least an effective amount, or at least an amount effective to produce a desired result, such as that associated with a particular goal or purpose, such as any described herein. The desired therapeutic result herein can include, without limitation, to treating, alleviating, or curing a disorder, cancer, an immune-associated disease, a CD200R associated disorder, and / or any symptoms from immune-related pathologies and the like as described in this specification and or appended claims.[000181] As used herein, "pharmaceutically acceptable carrier" or "pharmaceutical acceptable excipient" includes any material which, when combined with an active ingredient, allows the ingredient to retain biological activity and is non-reactive with the subject's immune system. Examples include, but are not limited to, any of the standard pharmaceutical carriers such as a phosphate buffered saline solution, water, emulsions such as oil / water emulsion, and various types of wetting agents. Preferred diluents for aerosol or parenteral administration are phosphate buffered saline or normal (0.9%) saline. Compositions comprising such carriers are formulated by well-known conventional methods (see, for example, Remington's Pharmaceutical Sciences, 18th edition, A. Gennaro, ed., Mack Publishing Co., Easton, PA, 1990; and Remington, The Science and Practice of Pharmacy 20th Ed. Mack Publishing, 2000).[000182] Throughout the specification and attached claims, the methods and systems of this disclosure as described herein may employ, unless otherwise indicated, conventional techniques and descriptions of molecular biology (including recombinant techniques), cell biology, biochemistry, microarray and sequencing technology, which are within the skill of those who practice in the art. Such conventional techniques include polymer array synthesis, hybridizationand ligation of oligonucleotides, sequencing of oligonucleotides, and detection of hybridization using a label. Specific illustrations of suitable techniques can be had by reference to the examples herein. However, equivalent conventional procedures can, of course, also be used. Such conventional techniques and descriptions can be found in standard laboratory manuals such as Green, et al., Eds., Genome Analysis: A Laboratory Manual Series (Vols. I-IV) (1999); Weiner, et al., Eds., Genetic Variation: A Laboratory Manual (2007); Dieffenbach, Dveksler, Eds., PCR Primer: A Laboratory Manual (2003); Bowtell and Sambrook, DNA Microarrays: A Molecular Cloning Manual (2003); Mount, Bioinformatics: Sequence and Genome Analysis (2004); Sambrook and Russell, Condensed Protocols from Molecular Cloning: A Laboratory Manual (2006); and Sambrook and Green, Molecular Cloning: A Laboratory Manual, 4th Edition (2012) (all from Cold Spring Harbor Laboratory Press); Stryer, L., Biochemistry (4th Ed.) W.H. Freeman, N.Y. (1995); Gait, “Oligonucleotide Synthesis: A Practical Approach" IRL Press, London (1984); Nelson and Cox, Lehninger, Principles of Biochemistry, 6thEd., W.H. Freeman Pub., New York (2012); R.I. Freshney, Culture of Animal Cells: A Manual of Basic Technique and Specialized Applications, 6thEd., Wiley-Blackwell (2010); and Berg et al., Biochemistry, 5thEd., W.H. Freeman Pub., New York (2002), all of which are herein incorporated by reference in their entirety for all purposes. Before the present compositions, research tools and systems and methods are described, it is to be understood that this disclosure is not limited to the specific systems and methods, compositions, targets and uses described, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular aspects only and is not intended to limit the scope of the present disclosure, which will be limited only by appended claims.[000183] The term “anti-CD200R antibody” or molecule as used herein, refers to both antibodies and binding fragments thereof capable of binding to CD200R.[000184] In the present disclosure, an “antibody” refers to an immunoglobulin molecule capable of specific binding to a target, such as a carbohydrate, polynucleotide, lipid, polypeptide, etc., through at least one antigen recognition site, located in the variable region of the immunoglobulin molecule. The term as used herein, includes an immunoglobulin molecule that specifically binds to an antigen and comprises an FcR binding site which may or may not be functional. As used in the disclosure, the term encompasses not only intact polyclonal or monoclonal antibodies, but also fragments thereof (such as Fab, Fab', F(ab')2, diabodies) Fv fragments and single chain (ScFv) mutants that contain an antigen recognition site or antigen binding site and have ability to bind to an antigen. Antigen-binding antibody or immunoglobulin fragments are well known in the art; such fragment can have a functional or non-functional Fc receptor binding site. Further as used herein, the term is not limited only to intact polyclonal ormonoclonal antibodies, multispecific antibodies such as bispecific, or polyspecific antibodies generated from at least two intact antibodies, chimeric antibodies, humanized antibodies, singlechain, chimeric, synthetic, recombinant, hybrid, mutated, grafted antibodies, human antibodies, and any other modified immunoglobulin molecule comprising an antigen binding site so long as the antibodies exhibit the desired biological activity.[000185] There are five major classes of immunoglobulins: IgA, IgD, IgE, IgG, and IgM, and several of these may be further divided into subclasses (isotypes), e.g., IgGl, IgG2, IgG3, IgG4, IgAl and IgA2. The heavy-chain constant domains that correspond to the different classes of immunoglobulins are called alpha, delta, epsilon, gamma, and mu, respectively. The subunit structures and three-dimensional configurations of different classes of immunoglobulins are well known. Unless dictated otherwise by contextual constraints the antibodies of the disclosure can be from one of these classes or subclasses of antibodies. Heavy-chain constant domains that correspond to the different classes of antibodies are typically denoted by the corresponding lower-case Greek letter a, 6, a, y, and p, respectively. Light chains of the antibodies from any vertebrate species can be assigned to one of two clearly distinct types, called kappa (K) and lambda (X), based on the amino acid sequences of their constant domains.[000186] Throughout the specification and appended claims, “Fc receptor” and “FcR” describe a receptor that binds to the Fc region of an antibody. FcRs are reviewed in Ravetch and Kinet, 1991, Ann. Rev. Immunol., 9:457-92; Capel et al., 1994, Immunomethods, 4:25-34; and de Haas et al., 1995, J. Lab. Clin. Med., 126:330-41. “FcR” also includes the neonatal receptor, FcRn, which is responsible for the transfer of maternal IgGs to the fetus (Guyer et al., 1976, J. Immunol., 117:587; and Kim et al., 1994, J. Immunol., 24:249).[000187] Wherever used herein, “monoclonal antibody” refers to an antibody obtained from a population of substantially homogeneous antibodies. In general, the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, in contrast to polyclonal antibody preparations, which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. The modifier “monoclonal” indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies and is not to be construed as requiring production of the antibody by any particular method. For example, the monoclonal antibodies to be used in accordance with the present disclosure may be made by the hybridoma method first described by Kohler and Milstein, 1975, Nature, 256:495, or may be made by recombinant DNA methods such as described in U.S. Pat. No. 4,816,567. The monoclonal antibodies may also be isolated fromphage libraries generated using the techniques described in McCafferty et al., 1990, Nature, 348:552-554, for example.[000188] Wherever used herein, “human antibody” means an antibody having an amino acid sequence corresponding to that of an antibody produced by a human and / or has been made using any of the techniques for making human antibodies known in the art or of the present disclosure. This definition of a human antibody includes antibodies comprising at least one human heavy chain polypeptide or at least one human light chain polypeptide. One such example is an antibody comprising murine light chain and human heavy chain polypeptides. Human antibodies can be produced using various techniques known in the art. In some cases, the human antibody is selected from a phage library, where that phage library expresses human antibodies (Vaughan et al., 1996, Nature Biotechnology, 14:309-314; Sheets et al., 1998, PNAS, (USA) 95:6157-6162; Hoogenboom and Winter, 1991, J. Mol. Biol., 227:381; Marks et al., 1991, J. Mol. Biol., 222:581). Human antibodies can also be made by introducing human immunoglobulin loci into transgenic animals, e.g., mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. This approach is described in U.S. Patent Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; and 5,661 ,016.Alternatively, the human antibody may be prepared by immortalizing human B lymphocytes that produce an antibody directed against a target antigen (such B lymphocytes may be recovered from an individual or may have been immunized in vitro). See, e.g., Cole et al., Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, p. 77 (1985); Boerner et al., 1991, J. Immunol., 147 (l):86-95; and U.S. Patent No. 5,750,373.[000189] As used herein, “humanized” antibodies refer to forms of non-human (e.g., murine) antibodies that are specific chimeric immunoglobulins, immunoglobulin chains, or fragments thereof (such as Fv, Fab, Fab', F(ab')2 or other antigen-binding subsequences of antibodies) that contain minimal sequence derived from non- human immunoglobulin. For the most part, humanized antibodies are human immunoglobulins (recipient antibody) in which residues from a complementarity determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat, or rabbit having the desired specificity, affinity, and biological activity. In some instances, Fv framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues. Furthermore, the humanized antibody may comprise residues that are found neither in the recipient antibody nor in the imported CDR or framework sequences but are included to further refine and optimize antibody performance. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and allor substantially all of the FR regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region or domain (Fc), typically that of a human immunoglobulin. Antibodies may have Fc regions modified as described in WO 99 / 58572. Other forms of humanized antibodies have one or more CDRs (one, two, three, four, five, six) which are altered with respect to the original antibody, which are also termed one or more CDRs “derived from” one or more CDRs from the original antibody.[000190] As used herein, the term “chimeric antibody” can refer to antibodies in which the variable region sequences are derived from one species and the constant region sequences are derived from another species, such as an antibody in which the variable region sequences are derived from a mouse antibody and the constant region sequences are derived from a human antibody. In some embodiments, the antibody provided herein is a monoclonal antibody.[000191] Wherever used herein “antibody-dependent cell-mediated cytotoxicity” and “ADCC” refer to a cell-mediated reaction in which nonspecific cytotoxic cells that express Fc receptors (FcRs) (e.g., natural killer (NK) cells, neutrophils, and macrophages) recognize bound antibody on a target cell and subsequently cause lysis of the target cell. ADCC activity of a molecule of interest can be assessed using an in vitro ADCC assay, such as that described in U.S. Patent No. 5,500,362 or 5,821,337. Useful effector cells for such assays include peripheral blood mononuclear cells (PBMC) and NK cells. Alternatively, or additionally, ADCC activity of the molecule of interest may be assessed in vivo, e.g., in an animal model such as that disclosed in Clynes et al., 1998, PNAS (USA), 95:652-656.[000192] “Complement dependent cytotoxicity” and “CDC” refer to the lysing of a target in the presence of complement. The complement activation pathway is initiated by the binding of the first component of the complement system (Clq) to a molecule (e.g., an antibody) complexed with a cognate antigen. To assess complement activation, a CDC assay, e.g., as described in Gazzano- Santoro et al., J. Immunol. Methods, 202: 163 (1996), may be performed.[000193] An antibody that "specifically binds" to an epitope is a term well understood in the art, and methods to determine such specific binding are also well known in the art. A molecule is said to exhibit "specific binding" if it reacts or associates more frequently, more rapidly, with greater duration and / or with greater affinity with a particular cell, protein or substance than it does with alternative cells, proteins or substances. An antibody “specifically binds” or “preferentially binds” to a target if it binds with greater affinity, avidity, more readily, and / or with greater duration than it binds to other substances. For example, an antibody that specifically or preferentially binds to CD200R is an antibody that binds this epitope with greater affinity, avidity, more readily, and / or with greater duration than it binds to other epitopes. As a furtherexample, an antibody (or other moiety) that specifically or preferentially binds to a first target may or may not specifically or preferentially bind to a second target. As such, “specific binding” or “preferential binding” does not necessarily require (although it can include) exclusive binding. Generally, but not necessarily, reference to binding means preferential binding.[000194] A “fragment” when applied to a protein, is a truncated form of a native biologically active protein that may or may not retain at least a portion of the therapeutic and / or biological activity. Herein, the terms “antibody fragment molecules of the disclosure”, “antibody fragment” and “antigen-binding fragment thereof’, are used interchangeably.[000195] Sequence Identity[000196] The sequence identity with respect to the anti-CD200R antibody or any other amino acid sequences identified herein, is defined as the percentage of amino acid residues in a query sequence that are identical with the amino acid residues of a second, reference polypeptide sequence or a portion thereof, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared. Percent identity may be measured over the length of an entire defined polypeptide sequence, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined polypeptide sequence, for instance, a fragment of at least 15, at least 20, at least 30, at least 40, at least 50, at least 70 or at least 150 contiguous residues. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in the tables, figures or Sequence Listing, may be used to describe a length over which percentage identity may be measured. In some embodiments, percent identity is determined with respect to the full length of a noted reference sequence, such as a sequence provided herein. For example, sequence comparison between two amino acid sequences (or a shorter length thereof) of the present disclosure may be carried out by computer program Blastp (protein-protein BLAST) provided online by Nation Center for Biotechnology Information (NCBI). The percentage amino acid sequence identity of a given amino acid sequence A to a given amino acid sequence B (which can alternatively be phrased as a given amino acid sequence A that has a certain % amino acid sequence identity to a given amino acid sequence B) is calculated by the formula as follows:X- x 100% where X is the number of amino acid residues scored as identical matches by the sequence alignment program BLAST in that program’s alignment of A and B, and where Y is the total number of amino acid residues in A or B, whichever is shorter.Two polynucleotide or polypeptide sequences are said to be "identical" if the sequence of nucleotides or amino acids in the two sequences is the same when aligned for maximum correspondence as described below. Comparisons between two sequences are typically performed by comparing the sequences over a comparison window to identify and compare local regions of sequence similarity.[000197] CD200 and CD200R[000198] In some aspects, provided herein are compositions and methods related to antibodies or antibody fragments that bind to and agonize CD200R, a receptor that can be present on the surface of immune cells including T cells, natural killer cells, B cells, monocytes, myeloid cells, macrophages, microglia and dendritic cells. CD200:CD200R plays a critical role in limiting immune cell proliferation, immune response, and inflammation.[000199] Without wishing to be bound by a certain theory, activation of the CD200R signaling pathway leads to inhibition of immune cell activation and proliferation. Antibodies that enhance CD200R signaling has the potential to downregulate inflammation and immune response in infection, arthritis, cancer, autoimmune diseases, transplant rejection, or other disease or condition associated with CD200R.CD200 is a member of the immunoglobulin superfamily (IgSF) and a transmembrane type la glycoprotein and can be highly expressed in a variety of cells types, for example, dendritic cells, macrophages, B lymphocytes, neuronal and endothelial cells, as well as in some T lymphocytes. CD200 has been implicated in inhibitory signaling which prohibits or reduces expression of genes involved in inflammatory responses. CD200 can function in concert with its natural receptor CD200R to activate the immunosuppression signaling cascade.[000200] Without wishing to be bound by a certain theory, in some cases, CD200R does not contain any immunoreceptor tyrosine-based inhibitory motifs (ITIMs), which are usually present in a large number of inhibitory receptors, and which can mediate their inhibitory roles through the recruitment of protein tyrosine phosphatases such as Src homology 2 domain-containing phosphatase (SHP) 1, SH2, or the inositol phosphatase (SHIP) upon phosphorylation. Instead, in some cases, the molecular signaling mechanism of CD200R following activation involves direct interaction of the adaptor protein downstream to tyrosine kinase (Dok2), with the CD200R membrane distal tyrosine residue located within a phosphotyrosine-binding (PTB) domainrecognition motif (NPxY). This interaction can lead to binding and recruitment of RAS p21 protein activator (RasGAP) which is an SH2 domain containing protein. The formation of the Dok2-RasGAP complex can inhibit Ras activation, leading to inhibition of other downstream inflammatory signals through inhibition of principal mitogen activated protein kinases including Phosphoinositide 3 -kinase (PI3K) and Extracellular Signal-regulated Kinase (Erk). In some cases, the interaction between CD200 and CD200R induces phosphorylation of tyrosine residues, initiating a signaling cascade which recruits SHIP and RasGAP. Dok2 can be regulated by Dokl through Crk Like (CrkL)-RasGAP suppression; both Dok2 and Dokl can be recruited during CD200-CD200R interaction that can lead to recruitment of RasGAP and SH2-containing inositol phosphatase. In some cases, Dokl activation is initiated through binding to one of the three phosphotyrosine residues located on the cytoplasmic amino acid chain of CD200R. This Dokl- phosphotyrosine binding can then suppress Dok2’s effect on Ras through activation of CrkL. [000201] In some aspects, provided herein are antibodies, compositions, nucleic acids, vectors, host cells, kits, uses thereof, and methods of making the same that can circumvent some of the aforementioned and other problems known in the art that are associated with existing anti- CD200R antibodies. In some embodiments, provided herein are CD200R agonist antibodies that enhance CD200R signaling by binding to CD200R on immune cells without competing with CD200.Antibody Sequence[000202] In the present disclosure, is provided herein compositions, therapeutics, kits, vectors, nucleic acid sequences, manufacturing, culturing and / or methods for producing an CD200R agonist antibody or an antigen-binding fragment or a functional fragment thereof that enhances the biological effects of CD200R activation, e.g., inhibiting the activity or proliferation of the immune cell that expresses the CD200R molecule the antibody binds to, or promoting downregulation of CD200R expressing immune cell responses and inflammatory responses. In some cases, a CD200R agonist antibody promotes the downstream signaling of CD200R that is triggered by CD200 binding. In some cases, a CD200R agonist antibody enhances the interaction between CD200 and CD200R. In some cases, a CD200R agonist antibody promotes the downstream signaling of CD200R without increasing or enhancing the interaction between CD200 and CD200R. In some cases, a CD200R agonist antibody activates or enhances CD200R signaling in the absence of CD200 binding to CD200R.[000203] In some embodiments, an antibody or an antigen-binding fragment (e.g., an isolated antibody) provided herein specifically binds to CD200R and enhances the CD200R signaling pathway of the cell has CD200R expressed on its surface.[000204] In some embodiments, an antibody or an antigen-binding fragment (e.g., an isolated antibody) provided herein is a CD200R antibody that comprises a heavy chain. In some embodiments, an antibody or an antigen-binding fragment provided herein is a CD200R antibody that comprises a light chain. In some embodiments, an antibody or an antigen-binding fragment provided herein is a CD200R antibody that comprises an Fc region.[000205] In some embodiments, the heavy chain further comprises at least one heavy chain complementarity determining region (CDR). In some embodiments, the heavy chain CDR comprises a sequence as set forth in any of SEQ ID NO: 3, 4, 41, 5, 11, 12, 13, 19, 20, 21, 27, 28, 29, 35, 36, 36, 69, 70, or 92, with from 0 to 3 amino acid modifications. In some embodiments, the heavy chain CDR comprises a sequence as set forth in any of SEQ ID NO: 3, 4, 41, 5, 11, 12, 13, 19, 20, 21, 27, 28, 29, 35, 36, 36, 69, 70, or 92, with from 0 to 2 amino acid modifications. In some embodiments, the heavy chain CDR comprises a sequence as set forth in any of SEQ ID NO: 3, 4, 41, 5, 11, 12, 13, 19, 20, 21, 27, 28, 29, 35, 36, 36, 69, 70, or 92, with from 0 to 1 amino acid modifications.[000206] In some embodiments, the heavy chain comprises a heavy chain variable region. In some cases, the heavy chain variable region comprises heavy chain complementarity determining region 1 (CDRH1), CDRH2, and CDRH3. In some cases, CDRH1, CDRH2, and CDRH3 comprise the sequence as set forth in SEQ ID NOs: 3, 41, and 70, respectively, each with 0 to 3 amino acid modifications, such as 0, 1, 2, or 3 modifications. In some cases, CDRH1, CDRH2, and CDRH3 comprise the sequence as set forth in SEQ ID NOs: 3, 41, and 5, respectively, each with 0 to 3 amino acid modifications, such as 0, 1, 2, or 3 modifications. In some cases, CDRH1, CDRH2, and CDRH3 comprise the sequence as set forth in SEQ ID NOs: 3, 4, and 5, respectively, each with 0 to 3 amino acid modifications, such as 0, 1, 2, or 3 modifications. In some cases, CDRH1, CDRH2, and CDRH3 comprise the sequence as set forth in SEQ ID NOs: 3, 41, and 5, respectively, each with 0 to 3 amino acid modifications, such as 0, 1, 2, or 3 modifications. In some cases, CDRH1, CDRH2, and CDRH3 comprise the sequence as set forth in SEQ ID NOs: 11, 12, and 13, respectively, each with 0 to 3 amino acid modifications, such as 0, 1, 2, or 3 modifications. In some cases, CDRH1, CDRH2, and CDRH3 comprise the sequence as set forth in SEQ ID NOs: 19, 20, and 21, respectively, each with 0 to 3 amino acid modifications, such as 0, 1, 2, or 3 modifications. In some cases, CDRH1, CDRH2, and CDRH3 comprise the sequence as set forth in SEQ ID NOs: 27, 28, and 29, respectively, each with 0 to 3 amino acid modifications, such as 0, 1, 2, or 3 modifications. In some cases, CDRH1, CDRH2, and CDRH3 comprise the sequence as set forth in SEQ ID NOs: 35, 36, and 37, respectively, each with 0 to 3 amino acid modifications, such as 0, 1, 2, or 3 modifications.[000207] In some embodiments, the light chain further comprises at least one light chain complementarity determining region (CDR). In some embodiments, the light chain CDR comprises a sequence as set forth in any of SEQ ID NO: 6, 7, 8, 14, 15, 16, 22, 23, 24, 30, 31, 32, 38, 39, 40, 67, 68, or 87 to 91, with from 0 to 3 amino acid modifications. In some embodiments, the light chain CDR comprises a sequence as set forth in any of SEQ ID NO: 6, 7, 8, 14, 15, 16, 22, 23, 24, 30, 31, 32, 38, 39, 40, 67, 68, or 87 to 91, with from 0 to 2 amino acid modifications. In some embodiments, the light chain CDR comprises a sequence as set forth in any of SEQ ID NO: 6, 7, 8, 14, 15, 16, 22, 23, 24, 30, 31, 32, 38, 39, 40, 67, 68, or 87 to 91, with from 0 to 1 amino acid modifications.[000208] In some embodiments, the heavy chain comprises a light chain variable region. In some cases, the light chain variable region comprises light chain complementarity determining region 1 (CDRL1), CDRL2, and CDRL3. In some cases, CDRL1, CDRL2, and CDRL3 comprise the sequence as set forth in SEQ ID NOs: 6, 7, and 8, respectively, each with 0 to 3 amino acid modifications, such as 0, 1, 2, or 3 modifications. In some cases, CDRL1, CDRL2, and CDRL3 comprise the sequence as set forth in SEQ ID NOs: 6, 67, and 8, respectively, each with 0 to 3 amino acid modifications, such as 0, 1, 2, or 3 modifications. In some cases, CDRL1, CDRL2, and CDRL3 comprise the sequence as set forth in SEQ ID NOs: 6, 68, and 8, respectively, each with 0 to 3 amino acid modifications, such as 0, 1, 2, or 3 modifications. In some cases, CDRL1, CDRL2, and CDRL3 comprise the sequence as set forth in SEQ ID NOs: 14, 15, and 16, respectively, each with 0 to 3 amino acid modifications, such as 0, 1, 2, or 3 modifications. In some cases, CDRL1, CDRL2, and CDRL3 comprise the sequence as set forth in SEQ ID NOs: 22, 23, and 24, respectively, each with 0 to 3 amino acid modifications, such as 0, 1, 2, or 3 modifications. In some cases, CDRL1, CDRL2, and CDRL3 comprise the sequence as set forth in SEQ ID NOs: 30, 31, and 32, respectively, each with 0 to 3 amino acid modifications, such as 0, 1, 2, or 3 modifications. In some cases, CDRL1, CDRL2, and CDRL3 comprise the sequence as set forth in SEQ ID NOs: 38, 39, and 40, respectively, each with 0 to 3 amino acid modifications, such as 0, 1, 2, or 3 modifications. In some cases, CDRL1, CDRL2, and CDRL3 comprise the sequence as set forth in SEQ ID NOs: 6, 7, and 8, respectively, each with 0 to 2 amino acid modifications. In some cases, CDRL1, CDRL2, and CDRL3 comprise the sequence as set forth in SEQ ID NOs: 6, 67, and 8, respectively, each with 0 to 2 amino acid modifications. In some cases, CDRL1, CDRL2, and CDRL3 comprise the sequence as set forth in SEQ ID NOs: 6, 68, and 8, respectively, each with 0 to 2 amino acid modifications. In some cases, CDRL1, CDRL2, and CDRL3 comprise the sequence as set forth in SEQ ID NOs: 14, 15, and 16, respectively, each with 0 to 2 amino acid modifications. In some cases, CDRL1, CDRL2, and CDRL3 comprise the sequence as set forth in SEQ ID NOs: 22, 23, and 24, respectively, eachwith 0 to 2 amino acid modifications. In some cases, CDRL1, CDRL2, and CDRL3 comprise the sequence as set forth in SEQ ID NOs: 30, 31, and 32, respectively, each with 0 to 2 amino acid modifications. In some cases, CDRL1, CDRL2, and CDRL3 comprise the sequence as set forth in SEQ ID NOs: 38, 39, and 40, respectively, each with 0 to 2 amino acid modifications. In some cases, CDRL1, CDRL2, and CDRL3 comprise the sequence as set forth in SEQ ID NOs: 14, 15, and 16, respectively, each with 0 to 2 amino acid modifications. In some cases, CDRL1, CDRL2, and CDRL3 comprise the sequence as set forth in SEQ ID NOs: 22, 23, and 24, respectively, each with 0 to 1 amino acid modifications. In some cases, CDRL1, CDRL2, and CDRL3 comprise the sequence as set forth in SEQ ID NOs: 30, 31, and 32, respectively, each with 0 to 1 amino acid modifications. In some cases, CDRL1, CDRL2, and CDRL3 comprise the sequence as set forth in SEQ ID NOs: 38, 39, and 40, respectively, each with 0 to 1 amino acid modifications.[000209] In some embodiments, the antibody provided herein (or antigen-binding fragment, hereafter referred to as “antibody,” to represent the full length antibody or the antigen-binding fragment of the antibody provided herein) comprises a heavy chain that comprises at least one heavy chain CDR as set forth in any of SEQ ID NO: 3, 4, 41, 5, 69, or 70, with from 0 to 3 amino acid modifications, and a light chain that comprises at least one light chain CDR as set forth in any of SEQ ID NO: 6, 7, or 8, with from 0 to 3 amino acid modifications. In some cases, the antibody provided herein comprises a heavy chain that comprises at least one heavy chain CDR as set forth in any of SEQ ID NO: 3, 4, 41, 5, 69, or 70, with from 0 to 3 amino acid modifications, and a light chain that comprises at least one light chain CDR as set forth in any of SEQ ID NO: 6, 67, or 8, with from 0 to 3 amino acid modifications. In some cases, the antibody provided herein comprises a heavy chain that comprises at least one heavy chain CDR as set forth in any of SEQ ID NO: 3, 4, 41, 5, 69, or 70, with from 0 to 3 amino acid modifications, and a light chain that comprises at least one light chain CDR as set forth in any of SEQ ID NO: 6, 68, or 8, with from 0 to 3 amino acid modifications. In some cases, the antibody provided herein comprises a heavy chain that comprises at least one heavy chain CDR as set forth in any of SEQ ID NO: 3, 41, or 70, with from 0 to 3 amino acid modifications, and a light chain that comprises at least one light chain CDR as set forth in any of SEQ ID NO: 6, 67, or 8 with from 0 to 3 amino acid modifications. In some cases, the antibody provided herein comprises a heavy chain that comprises at least one heavy chain CDR as set forth in any of SEQ ID NO: 3, 41, or 69, with from 0 to 3 amino acid modifications, and a light chain that comprises at least one light chain CDR as set forth in any of SEQ ID NO: 6, 67, or 8 with from 0 to 3 amino acid modifications. In some cases, the antibody provided herein comprises a heavy chain that comprises at least one heavy chain CDR as set forth in any of SEQ ID NO: 11, 12, or 13, with from 0 to 3 amino acidmodifications, and a light chain that comprises at least one light chain CDR as set forth in any of SEQ ID NO: 14, 15, or 16, with from 0 to 3 amino acid modifications. In some cases, the antibody provided herein comprises a heavy chain that comprises at least one heavy chain CDR as set forth in any of SEQ ID NO: 19, 20, or 21, with from 0 to 3 amino acid modifications, and a light chain that comprises at least one light chain CDR as set forth in any of SEQ ID NO: 22, 23, or 24, with from 0 to 3 amino acid modifications. In some cases, the antibody provided herein comprises a heavy chain that comprises at least one heavy chain CDR as set forth in any of SEQ ID NO: 27, 28, or 29, with from 0 to 3 amino acid modifications, and a light chain that comprises at least one light chain CDR as set forth in any of SEQ ID NO: 30, 31, or 32, with from 0 to 3 amino acid modifications. In some cases, the antibody provided herein comprises a heavy chain that comprises at least one heavy chain CDR as set forth in any of SEQ ID NO: 35, 36, or 37, with from 0 to 3 amino acid modifications, and a light chain that comprises at least one light chain CDR as set forth in any of SEQ ID NO: 38, 39, or 40, with from 0 to 3 amino acid modifications.[000210] In some cases, the antibody provided herein comprises a heavy chain that comprises at least one heavy chain CDR as set forth in any of SEQ ID NO: 3, 4, 41, 5, 69, or 70, with from 0 to 2 amino acid modifications, and a light chain that comprises at least one light chain CDR as set forth in any of SEQ ID NO: 6, 7, or 8, with from 0 to 2 amino acid modifications. In some cases, the antibody provided herein comprises a heavy chain that comprises at least one heavy chain CDR as set forth in any of SEQ ID NO: 3, 4, 41, 5, 69, or 70, with from 0 to 2 amino acid modifications, and a light chain that comprises at least one light chain CDR as set forth in any of SEQ ID NO: 6, 67, or 8, with from 0 to 2 amino acid modifications. In some cases, the antibody provided herein comprises a heavy chain that comprises at least one heavy chain CDR as set forth in any of SEQ ID NO: 3, 4, 41, 5, 69, or 70, with from 0 to 2 amino acid modifications, and a light chain that comprises at least one light chain CDR as set forth in any of SEQ ID NO: 6, 68, or 8, with from 0 to 2 amino acid modifications. In some cases, the antibody provided herein comprises a heavy chain that comprises at least one heavy chain CDR as set forth in any of SEQ ID NO: 11, 12, or 13, with from 0 to 2 amino acid modifications, and a light chain that comprises at least one light chain CDR as set forth in any of SEQ ID NO: 14, 15, or 16, with from 0 to 2 amino acid modifications. In some cases, the antibody provided herein comprises a heavy chain that comprises at least one heavy chain CDR as set forth in any of SEQ ID NO: 19, 20, or 21, with from 0 to 2 amino acid modifications, and a light chain that comprises at least one light chain CDR as set forth in any of SEQ ID NO: 22, 23, or 24, with from 0 to 2 amino acid modifications. In some cases, the antibody provided herein comprises a heavy chain that comprises at least one heavy chain CDRas set forth in any of SEQ ID NO: 27, 28, or 29, with from 0 to 2 amino acid modifications, and a light chain that comprises at least one light chain CDR as set forth in any of SEQ ID NO: 30, 31, or 32, with from 0 to 2 amino acid modifications. In some cases, the antibody provided herein comprises a heavy chain that comprises at least one heavy chain CDR as set forth in any of SEQ ID NO: 35, 36, or 37, with from 0 to 2 amino acid modifications, and a light chain that comprises at least one light chain CDR as set forth in any of SEQ ID NO: 38, 39, or 40, with from 0 to 2 amino acid modifications.[000211] In some cases, the antibody provided herein comprises a heavy chain that comprises at least one heavy chain CDR as set forth in any of SEQ ID NO: 3, 4, 41, 5, 69, or 70, with from 0 to 2 amino acid modifications, and a light chain that comprises at least one light chain CDR as set forth in any of SEQ ID NO: 6, 7, or 8, with from 0 to 1 amino acid modifications. In some cases, the antibody provided herein comprises a heavy chain that comprises at least one heavy chain CDR as set forth in any of SEQ ID NO: 3, 4, 41, 5, 69, or 70, with from 0 to 2 amino acid modifications, and a light chain that comprises at least one light chain CDR as set forth in any of SEQ ID NO: 6, 67, or 8, with from 0 to 1 amino acid modifications. In some cases, the antibody provided herein comprises a heavy chain that comprises at least one heavy chain CDR as set forth in any of SEQ ID NO: 3, 4, 41, 5, 69, or 70, with from 0 to 2 amino acid modifications, and a light chain that comprises at least one light chain CDR as set forth in any of SEQ ID NO: 6, 68, or 8, with from 0 to 1 amino acid modifications. In some cases, the antibody provided herein comprises a heavy chain that comprises at least one heavy chain CDR as set forth in any of SEQ ID NO: 11, 12, or 13, with from 0 to 1 amino acid modifications, and a light chain that comprises at least one light chain CDR as set forth in any of SEQ ID NO: 14, 15, or 16, with from 0 to 1 amino acid modifications. In some cases, the antibody provided herein comprises a heavy chain that comprises at least one heavy chain CDR as set forth in any of SEQ ID NO: 19, 20, or 21, with from 0 to 1 amino acid modifications, and a light chain that comprises at least one light chain CDR as set forth in any of SEQ ID NO: 22, 23, or 24, with from 0 to 1 amino acid modifications. In some cases, the antibody provided herein comprises a heavy chain that comprises at least one heavy chain CDR as set forth in any of SEQ ID NO: 27, 28, or 29, with from 0 to 1 amino acid modifications, and a light chain that comprises at least one light chain CDR as set forth in any of SEQ ID NO: 30, 31, or 32, with from 0 to 1 amino acid modifications. In some cases, the antibody provided herein comprises a heavy chain that comprises at least one heavy chain CDR as set forth in any of SEQ ID NO: 35, 36, or 37, with from 0 to 1 amino acid modifications, and a light chain that comprises at least one light chain CDR as set forth in any of SEQ ID NO: 38, 39, or 40, with from 0 to 1 amino acid modifications.[000212] In some embodiments, the antibody provided herein comprises a heavy chain comprising a heavy chain variable region that further comprises heavy chain complementarity determining region 1 (CDRH1), CDRH2, and CDRH3 and a light chain comprising a light chain variable region that comprises light chain complementarity determining region 1 (CDRL1), CDRL2, and CDRL3, wherein CDRL1, CDRL2, and CDRL3. In some cases, the CDRH1, CDRH2, and CDRH3 comprise the sequence as set forth in SEQ ID NOs: 3, 4, and 5, respectively, each with 0 to 3 amino acid modifications, such as 0, 1, 2, or 3 modifications and the CDRL1, CDRL2, and CDRL3 comprise the sequence as set forth in SEQ ID NOs: 6, 7, and 8, respectively, each with 0 to 3 amino acid modifications, such as 0, 1, 2, or 3 modifications. In some cases, the CDRH1, CDRH2, and CDRH3 comprise the sequence as set forth in SEQ ID NOs: 3, 4, and 5, respectively, each with 0 to 3 amino acid modifications, such as 0, 1, 2, or 3 modifications and the CDRL1, CDRL2, and CDRL3 comprise the sequence as set forth in SEQ ID NOs: 6, 67, and 8, respectively, each with 0 to 3 amino acid modifications, such as 0, 1, 2, or 3 modifications. In some cases, the CDRH1, CDRH2, and CDRH3 comprise the sequence as set forth in SEQ ID NOs: 3, 41, 69, respectively, each with 0 to 3 amino acid modifications, such as 0, 1, 2, or 3 modifications and the CDRL1, CDRL2, and CDRL3 comprise the sequence as set forth in SEQ ID NOs: 6, 67, and 8, respectively, each with 0 to 3 amino acid modifications, such as 0, 1, 2, or 3 modifications. In some cases, the CDRH1, CDRH2, and CDRH3 comprise the sequence as set forth in SEQ ID NOs: 3, 41, 70, respectively, each with 0 to 3 amino acid modifications, such as 0, 1, 2, or 3 modifications and the CDRL1, CDRL2, and CDRL3 comprise the sequence as set forth in SEQ ID NOs: 6, 67, and 8, respectively, each with 0 to 3 amino acid modifications, such as 0, 1, 2, or 3 modifications. In some cases, the CDRH1, CDRH2, and CDRH3 comprise the sequence as set forth in SEQ ID NOs: 3, 4, and 5, respectively, each with 0 to 3 amino acid modifications, such as 0, 1, 2, or 3 modifications and the CDRL1, CDRL2, and CDRL3 comprise the sequence as set forth in SEQ ID NOs: 6, 68, and 8, respectively, each with 0 to 3 amino acid modifications, such as 0, 1, 2, or 3 modifications. In some cases, the CDRH1, CDRH2, and CDRH3 comprise the sequence as set forth in SEQ ID NOs: 3, 41, and 5, respectively, each with 0 to 3 amino acid modifications, such as 0, 1, 2, or 3 modifications, and the CDRL1, CDRL2, and CDRL3 comprise the sequence as set forth in SEQ ID NOs: 6, 7, and 8, respectively, each with 0 to 3 amino acid modifications, such as 0, 1, 2, or 3 modifications. In some cases, the CDRH1, CDRH2, and CDRH3 comprise the sequence as set forth in SEQ ID NOs: 3, 41, and 5, respectively, each with 0 to 3 amino acid modifications, such as 0, 1, 2, or 3 modifications, and the CDRL1, CDRL2, and CDRL3 comprise the sequence as set forth in SEQ ID NOs: 6, 67, and 8, respectively, each with 0 to 3 amino acid modifications, such as 0, 1, 2, or 3 modifications. In some cases, the CDRH1, CDRH2, and CDRH3 comprise the sequence as setforth in SEQ ID NOs: 3, 41, and 5, respectively, each with 0 to 3 amino acid modifications, such as 0, 1, 2, or 3 modifications, and the CDRL1, CDRL2, and CDRL3 comprise the sequence as set forth in SEQ ID NOs: 6, 68, and 8, respectively, each with 0 to 3 amino acid modifications, such as 0, 1, 2, or 3 modifications. In some cases, the CDRH1, CDRH2, and CDRH3 comprise the sequence as set forth in SEQ ID NOs: 11, 12, and 13, respectively, each with 0 to 3 amino acid modifications, such as 0, 1, 2, or 3 modifications, and the CDRL1, CDRL2, and CDRL3 comprise the sequence as set forth in SEQ ID NOs: 14, 15, and 16, respectively, each with 0 to 3 amino acid modifications, such as 0, 1, 2, or 3 modifications. In some cases, the CDRH1, CDRH2, and CDRH3 comprise the sequence as set forth in SEQ ID NOs: 19, 20, and 21, respectively, each with 0 to 3 amino acid modifications, such as 0, 1, 2, or 3 modifications, and the CDRL1, CDRL2, and CDRL3 comprise the sequence as set forth in SEQ ID NOs: 22, 23, and 24, respectively, each with 0 to 3 amino acid modifications, such as 0, 1, 2, or 3 modifications. In some cases, the CDRH1, CDRH2, and CDRH3 comprise the sequence as set forth in SEQ ID NOs: 27, 28, and 29, respectively, each with 0 to 3 amino acid modifications, such as 0, 1, 2, or 3 modifications, and the CDRL1, CDRL2, and CDRL3 comprise the sequence as set forth in SEQ ID NOs: 30, 31, and 32, respectively, each with 0 to 3 amino acid modifications, such as 0, 1, 2, or 3 modifications. In some cases, the CDRH1, CDRH2, and CDRH3 comprise the sequence as set forth in SEQ ID NOs: 35, 36, and 37, respectively, each with 0 to 3 amino acid modifications, such as 0, 1, 2, or 3 modifications, and the CDRL1, CDRL2, and CDRL3 comprise the sequence as set forth in SEQ ID NOs: 38, 39, and 40, respectively, each with 0 to 3 amino acid modifications, such as 0, 1, 2, or 3 modifications. [000213] In some cases, the CDRH1, CDRH2, and CDRH3 comprise the sequence as set forth in SEQ ID NOs: 3, 4, and 5, respectively, each with 0 to 2 amino acid modifications and the CDRL1, CDRL2, and CDRL3 comprise the sequence as set forth in SEQ ID NOs: 6, 7, and 8, respectively, each with 0 to 2 amino acid modifications. In some cases, the CDRH1, CDRH2, and CDRH3 comprise the sequence as set forth in SEQ ID NOs: 3, 4, and 5, respectively, each with 0 to 2 amino acid modifications and the CDRL1, CDRL2, and CDRL3 comprise the sequence as set forth in SEQ ID NOs: 6, 67, and 8, respectively, each with 0 to 2 amino acid modifications. In some cases, the CDRH1, CDRH2, and CDRH3 comprise the sequence as set forth in SEQ ID NOs: 3, 41, 69, respectively, each with 0 to 2 amino acid modifications and the CDRL1, CDRL2, and CDRL3 comprise the sequence as set forth in SEQ ID NOs: 6, 67, and 8, respectively, each with 0 to 2 amino acid modifications. In some cases, the CDRH1, CDRH2, and CDRH3 comprise the sequence as set forth in SEQ ID NOs: 3, 41, 70, respectively, each with 0 to 2 amino acid modifications and the CDRL1, CDRL2, and CDRL3 comprise the sequence as set forth in SEQ ID NOs: 6, 67, and 8, respectively, each with 0 to 2 amino acidmodifications. In some cases, the CDRH1, CDRH2, and CDRH3 comprise the sequence as set forth in SEQ ID NOs: 3, 4, and 5, respectively, each with 0 to 2 amino acid modifications and the CDRL1, CDRL2, and CDRL3 comprise the sequence as set forth in SEQ ID NOs: 6, 68, and 8, respectively, each with 0 to 2 amino acid modifications. In some cases, the CDRH1, CDRH2, and CDRH3 comprise the sequence as set forth in SEQ ID NOs: 3, 41, and 5, respectively, each with 0 to 2 amino acid modifications, and the CDRL1, CDRL2, and CDRL3 comprise the sequence as set forth in SEQ ID NOs: 6, 7, and 8, respectively, each with 0 to 2 amino acid modifications. In some cases, the CDRH1, CDRH2, and CDRH3 comprise the sequence as set forth in SEQ ID NOs: 3, 41, and 5, respectively, each with 0 to 2 amino acid modifications, and the CDRL1, CDRL2, and CDRL3 comprise the sequence as set forth in SEQ ID NOs: 6, 67, and 8, respectively, each with 0 to 2 amino acid modifications. In some cases, the CDRH1, CDRH2, and CDRH3 comprise the sequence as set forth in SEQ ID NOs: 3, 41, and 5, respectively, each with 0 to 2 amino acid modifications, and the CDRL1, CDRL2, and CDRL3 comprise the sequence as set forth in SEQ ID NOs: 6, 68, and 8, respectively, each with 0 to 2 amino acid modifications. In some cases, the CDRH1, CDRH2, and CDRH3 comprise the sequence as set forth in SEQ ID NOs: 11, 12, and 13, respectively, each with 0 to 2 amino acid modifications, and the CDRL1, CDRL2, and CDRL3 comprise the sequence as set forth in SEQ ID NOs: 14, 15, and 16, respectively, each with 0 to 2 amino acid modifications. In some cases, the CDRH1, CDRH2, and CDRH3 comprise the sequence as set forth in SEQ ID NOs: 19, 20, and 21, respectively, each with 0 to 2 amino acid modifications, and the CDRL1, CDRL2, and CDRL3 comprise the sequence as set forth in SEQ ID NOs: 22, 23, and 24, respectively, each with 0 to 2 amino acid modifications. In some cases, the CDRH1, CDRH2, and CDRH3 comprise the sequence as set forth in SEQ ID NOs: 27, 28, and 29, respectively, each with 0 to 2 amino acid modifications, and the CDRL1, CDRL2, and CDRL3 comprise the sequence as set forth in SEQ ID NOs: 30, 31, and 32, respectively, each with 0 to 2 amino acid modifications. In some cases, the CDRH1, CDRH2, and CDRH3 comprise the sequence as set forth in SEQ ID NOs: 35, 36, and 37, respectively, each with 0 to 2 amino acid modifications, and the CDRL1, CDRL2, and CDRL3 comprise the sequence as set forth in SEQ ID NOs: 38, 39, and 40, respectively, each with 0 to 2 amino acid modifications.[000214] In some cases, the CDRH1, CDRH2, and CDRH3 comprise the sequence as set forth in SEQ ID NOs: 3, 4, and 5, respectively, each with 0 to 1 amino acid modifications and the CDRL1, CDRL2, and CDRL3 comprise the sequence as set forth in SEQ ID NOs: 6, 7, and 8, respectively, each with 0 to 1 amino acid modifications. In some cases, the CDRH1, CDRH2, and CDRH3 comprise the sequence as set forth in SEQ ID NOs: 3, 4, and 5, respectively, each with 0 to 1 amino acid modifications and the CDRL1, CDRL2, and CDRL3 comprise thesequence as set forth in SEQ ID NOs: 6, 67, and 8, respectively, each with 0 to 1 amino acid modifications. In some cases, the CDRH1, CDRH2, and CDRH3 comprise the sequence as set forth in SEQ ID NOs: 3, 41, 69, respectively, each with 0 to 1 amino acid modifications and the CDRL1, CDRL2, and CDRL3 comprise the sequence as set forth in SEQ ID NOs: 6, 67, and 8, respectively, each with 0 to 1 amino acid modifications. In some cases, the CDRH1, CDRH2, and CDRH3 comprise the sequence as set forth in SEQ ID NOs: 3, 41, 70, respectively, each with 0 to 1 amino acid modifications and the CDRL1, CDRL2, and CDRL3 comprise the sequence as set forth in SEQ ID NOs: 6, 67, and 8, respectively, each with 0 to 1 amino acid modifications. In some cases, the CDRH1, CDRH2, and CDRH3 comprise the sequence as set forth in SEQ ID NOs: 3, 4, and 5, respectively, each with 0 to 1 amino acid modifications and the CDRL1, CDRL2, and CDRL3 comprise the sequence as set forth in SEQ ID NOs: 6, 68, and 8, respectively, each with 0 to 1 amino acid modifications. In some cases, the CDRH1, CDRH2, and CDRH3 comprise the sequence as set forth in SEQ ID NOs: 3, 41, and 5, respectively, each with 0 to 1 amino acid modifications, and the CDRL1, CDRL2, and CDRL3 comprise the sequence as set forth in SEQ ID NOs: 6, 7, and 8, respectively, each with 0 to 1 amino acid modifications. In some cases, the CDRH1, CDRH2, and CDRH3 comprise the sequence as set forth in SEQ ID NOs: 3, 41, and 5, respectively, each with 0 to 1 amino acid modifications, and the CDRL1, CDRL2, and CDRL3 comprise the sequence as set forth in SEQ ID NOs: 6, 67, and 8, respectively, each with 0 to 1 amino acid modifications. In some cases, the CDRH1, CDRH2, and CDRH3 comprise the sequence as set forth in SEQ ID NOs: 3, 41, and 5, respectively, each with 0 to 1 amino acid modifications, and the CDRL1, CDRL2, and CDRL3 comprise the sequence as set forth in SEQ ID NOs: 6, 68, and 8, respectively, each with 0 to 1 amino acid modifications. In some cases, the CDRH1, CDRH2, and CDRH3 comprise the sequence as set forth in SEQ ID NOs: 11, 12, and 13, respectively, each with 0 to 1 amino acid modifications, and the CDRL1, CDRL2, and CDRL3 comprise the sequence as set forth in SEQ ID NOs: 14, 15, and 16, respectively, each with 0 to 1 amino acid modifications. In some cases, the CDRH1, CDRH2, and CDRH3 comprise the sequence as set forth in SEQ ID NOs: 19, 20, and 21, respectively, each with 0 to 1 amino acid modifications, and the CDRL1, CDRL2, and CDRL3 comprise the sequence as set forth in SEQ ID NOs: 22, 23, and 24, respectively, each with 0 to 1 amino acid modifications. In some cases, the CDRH1, CDRH2, and CDRH3 comprise the sequence as set forth in SEQ ID NOs: 27, 28, and 29, respectively, each with 0 to 1 amino acid modifications, and the CDRL1, CDRL2, and CDRL3 comprise the sequence as set forth in SEQ ID NOs: 30, 31, and 32, respectively, each with 0 to 1 amino acid modifications. In some cases, the CDRH1, CDRH2, and CDRH3 comprise the sequence as set forth in SEQ ID NOs: 35, 36, and 37, respectively, each with 0 to 1 amino acid modifications, and the CDRL1, CDRL2, andCDRL3 comprise the sequence as set forth in SEQ ID NOs: 38, 39, and 40, respectively, each with 0 to 1 amino acid modifications.[000215] In some embodiments, the antibody provided herein comprises a heavy chain variable region that comprises an amino acid sequence having at least 90% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 1, 9, 17, 25, 33, 42, 43, 44, 45, 46, 47, 71, 72, or 93. In some embodiments, the antibody provided herein comprises a heavy chain variable region that comprises an amino acid sequence having at least 95% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 1, 9, 17, 25, 33, 42, 43, 44, 45, 46, 47, 71, 72, or 93. In some embodiments, the antibody provided herein comprises a heavy chain variable region that comprises an amino acid sequence having at least 96% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 1, 9, 17, 25, 33, 42, 43, 44, 45, 46, 47, 71, 72, or 93. In some embodiments, the antibody provided herein comprises a heavy chain variable region that comprises an amino acid sequence having at least 97% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 1, 9, 17, 25, 33, 42, 43, 44, 45, 46, 47, 71, 72, or 93. In some embodiments, the antibody provided herein comprises a heavy chain variable region that comprises an amino acid sequence having at least 98% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 1, 9, 17, 25, 33, 42, 43, 44, 45, 46, 47, 71, 72, or 93. In some embodiments, the antibody provided herein comprises a heavy chain variable region that comprises an amino acid sequence having at least 99% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 1, 9, 17, 25, 33, 42, 43, 44, 45, 46, 47, 71, 72, or 93. In some embodiments, the antibody provided herein comprises a heavy chain variable region that comprises an amino acid sequence having 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 1, 9, 17, 25, 33, 42, 43, 44, 45, 46, 47, 71, 72, or 93.[000216] In some embodiments, the antibody provided herein comprises a heavy chain variable region that comprises an amino acid sequence as set forth in SEQ ID NO: 1, 9, 17, 25, 33, 42, 43, 44, 45, 46, 47, 71, 72, or 93with from 0 to 3 amino acid modifications. In some embodiments, the antibody provided herein comprises a heavy chain variable region that comprises an amino acid sequence as set forth in SEQ ID NO: 1, 9, 17, 25, 33, 42, 43, 44, 45, 46, 47, 71, 72, or 93 with from 0 to 2 amino acid modifications. In some embodiments, the antibody provided herein comprises a heavy chain variable region that comprises an amino acid sequence as set forth in SEQ ID NO: 1, 9, 17, 25, 33, 42, 43, 44, 45, 46, 47, 71, 72, or 93with from 0 to 2 amino acid modifications. In some embodiments, the antibody provided herein comprises a heavy chain variable region that comprises an amino acid sequence as set forth in SEQ ID NO: 1, 9, 17, 25, 33, 42, 43, 44, 45, 46, 47, 71, 72, or 93with from 0 to 1 amino acid modifications. In some embodiments, the antibody provided herein comprises a heavy chain variable region thatcomprises an amino acid sequence as set forth in SEQ ID NO: 1, 9, 17, 25, 33, 42, 43, 44, 45, 46, 47, 71, 72, or 93.[000217] In some embodiments, the antibody provided herein comprises a light chain variable region that comprises an amino acid sequence having at least 90% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 2, 10, 18, 26, 34, 48, 49, 50, 51, 52, 65, 66, or 94. In some embodiments, the antibody provided herein comprises a light chain variable region that comprises an amino acid sequence having at least 95% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 2, 10, 18, 26, 34, 48, 49, 50, 51, 52, 65, 66, or 94. In some embodiments, the antibody provided herein comprises a light chain variable region that comprises an amino acid sequence having at least 96% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 2, 10, 18, 26, 34, 48, 49, 50, 51, 52, 65, 66, or 94. In some embodiments, the antibody provided herein comprises a light chain variable region that comprises an amino acid sequence having at least 97% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 2, 10, 18, 26, 34, 48, 49, 50, 51, 52, 65, 66, or 94. In some embodiments, the antibody provided herein comprises a light chain variable region that comprises an amino acid sequence having at least 98% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 2, 10, 18, 26, 34, 48, 49, 50, 51, 52, 65, 66, or 94. In some embodiments, the antibody provided herein comprises a light chain variable region that comprises an amino acid sequence having at least 99% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 2, 10, 18, 26, 34, 48, 49, 50, 51, 52, 65, 66, or 94. In some embodiments, the antibody provided herein comprises a light chain variable region that comprises an amino acid sequence having at 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 2, 10, 18, 26, 34, 48, 49, 50, 51, 52, 65, 66, or 94.[000218] In some embodiments, the antibody provided herein comprises a light chain variable region that comprises an amino acid sequence as set forth in SEQ ID NO: 2, 10, 18, 26, 34, 48, 49, 50, 51, 52, 65, 66, or 94, with from 0 to 3 amino acid modifications. In some embodiments, the antibody provided herein comprises a light chain variable region that comprises an amino acid sequence as set forth in SEQ ID NO: 2, 10, 18, 26, 34, 48, 49, 50, 51, 52, 65, 66, or 94, with from 0 to 2 amino acid modifications. In some embodiments, the antibody provided herein comprises a light chain variable region that comprises an amino acid sequence as set forth in SEQ ID NO: 2, 10, 18, 26, 34, 48, 49, 50, 51, 52, 65, 66, or 94, with from 0 to 1 amino acid modifications. In some embodiments, the antibody provided herein comprises a light chain variable region that comprises an amino acid sequence as set forth in SEQ ID NO: 2, 10, 18, 26, 34, 48, 49, 50, 51, 52, 65, 66, or 94.[000219] In some embodiments, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having at least 90% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having at least 90% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 2. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 2. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having at least 96% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having at least 96% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 2. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having at least 97% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having at least 97% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 2. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having at least 98% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having at least 98% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 2. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having at least 99% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having at least 99% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 2. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 2.[000220] In some embodiments, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having at least 90% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 9, and a light chain variable region comprising an amino acid sequence having at least 90% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 10. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having at least 95% sequence identity to theamino acid sequence as set forth in SEQ ID NO: 9, and a light chain variable region comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 10. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having at least 96% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 9, and a light chain variable region comprising an amino acid sequence having at least 96% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 10. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having at least 97% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 9, and a light chain variable region comprising an amino acid sequence having at least 97% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 10. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having at least 98% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 9, and a light chain variable region comprising an amino acid sequence having at least 98% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 10. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having at least 99% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 9, and a light chain variable region comprising an amino acid sequence having at least 99% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 10. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 9, and a light chain variable region comprising an amino acid sequence having 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 10.[000221] In some embodiments, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having at least 90% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 17, and a light chain variable region comprising an amino acid sequence having at least 90% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 18. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 17, and a light chain variable region comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 18. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having at least 96% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 17, and a light chain variable region comprising an amino acid sequence having at least 96% sequence identity to the amino acid sequence as setforth in SEQ ID NO: 18. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having at least 97% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 17, and a light chain variable region comprising an amino acid sequence having at least 97% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 18. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having at least 98% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 17, and a light chain variable region comprising an amino acid sequence having at least 98% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 18. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having at least 99% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 17, and a light chain variable region comprising an amino acid sequence having at least 99% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 18. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 17, and a light chain variable region comprising an amino acid sequence having 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 18.[000222] In some embodiments, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having at least 90% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 25, and a light chain variable region comprising an amino acid sequence having at least 90% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 26. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 25, and a light chain variable region comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 26. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having at least 96% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 25, and a light chain variable region comprising an amino acid sequence having at least 96% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 26. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having at least 97% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 25, and a light chain variable region comprising an amino acid sequence having at least 97% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 26. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having at least 98% sequence identity to theamino acid sequence as set forth in SEQ ID NO: 25, and a light chain variable region comprising an amino acid sequence having at least 98% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 26. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having at least 99% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 25, and a light chain variable region comprising an amino acid sequence having at least 99% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 26. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 25, and a light chain variable region comprising an amino acid sequence having 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 26.[000223] In some embodiments, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having at least 90% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 33, and a light chain variable region comprising an amino acid sequence having at least 90% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 34. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 33, and a light chain variable region comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 34. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having at least 96% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 33, and a light chain variable region comprising an amino acid sequence having at least 96% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 34. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having at least 97% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 33, and a light chain variable region comprising an amino acid sequence having at least 97% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 34. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having at least 98% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 33, and a light chain variable region comprising an amino acid sequence having at least 98% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 34. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having at least 99% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 33, and a light chain variable region comprising an amino acid sequence having at least 99% sequence identity to the amino acid sequence as setforth in SEQ ID NO: 34. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 33, and a light chain variable region comprising an amino acid sequence having 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 34.[000224] In some embodiments, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having at least 90% sequence identity to the amino acid sequence as set forth in any one of SEQ ID NOs: 1, 42, 43, 44, 45, 46, 47, 71, 72, or 93 and a light chain variable region comprising an amino acid sequence having at least 90% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 2, 48, 49, 50, 51, 52, 65, 66, or 94. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence as set forth in any one of SEQ ID NOs: 1, 42, 43, 44, 45, 46, 47, 71, 72, or 93 and a light chain variable region comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 2, 48, 49, 50, 51, 52, 65, 66, or 94. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having at least 96% sequence identity to the amino acid sequence as set forth in any one of SEQ ID NOs: 1, 42, 43, 44, 45, 46, 47, 71, 72, or 93 and a light chain variable region comprising an amino acid sequence having at least 96% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 2, 48, 49, 50, 51, 52, 65, 66, or 94. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having at least 97% sequence identity to the amino acid sequence as set forth in any one of SEQ ID NOs: 1, 42, 43, 44, 45, 46, 47, 71, 72, or 93 and a light chain variable region comprising an amino acid sequence having at least 97% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 2, 48, 49, 50, 51, 52, 65, 66, or 94. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having at least 98% sequence identity to the amino acid sequence as set forth in any one of SEQ ID NOs: 1, 42, 43, 44, 45, 46, 47, 71, 72, or 93 and a light chain variable region comprising an amino acid sequence having at least 98% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 2, 48, 49, 50, 51, 52, 65, 66, or 94. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having at least 99% sequence identity to the amino acid sequence as set forth in any one of SEQ ID NOs: 1, 42, 43, 44, 45, 46, 47, 71, 72, or 93 and a light chain variable region comprising an amino acid sequence having at least 99% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 2, 48, 49, 50, 51, 52, 65, 66, or94. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having 100% sequence identity to the amino acid sequence as set forth in any one of SEQ ID NOs: 1, 42, 43, 44, 45, 46, 47, 71, 72, or 93 and a light chain variable region comprising an amino acid sequence having 100% sequence identity to the amino acid sequence as set forth in SEQ ID NO: 2, 48, 49, 50, 51, 52, 65, 66, or 94.[000225] In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having at least 90% sequence identity to the amino acid sequence as set forth in any one of SEQ ID NOs: 42, 43, 44, 45, 46, 47, 71, 72, or 93 and a light chain variable region comprising an amino acid sequence having at least 90% sequence identity to the amino acid sequence as set forth in SEQ ID NOS: 48, 49, 50, 51, 52, 65, 66, or 94. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence as set forth in any one of SEQ ID NOs: 42, 43, 44, 45, 46, 47, 71, 72, or 93 and a light chain variable region comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence as set forth in SEQ ID NOS: 48, 49, 50, 51, 52, 65, 66, or 94. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having at least 96% sequence identity to the amino acid sequence as set forth in any one of SEQ ID NOs: 42, 43, 44, 45, 46, 47, 71, 72, or 93 and a light chain variable region comprising an amino acid sequence having at least 96 % sequence identity to the amino acid sequence as set forth in SEQ ID NOS: 48, 49, 50, 51, 52, 65, 66, or 94. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having at least 97% sequence identity to the amino acid sequence as set forth in any one of SEQ ID NOs: 42, 43, 44, 45, 46, 47, 71, 72, or 93 and a light chain variable region comprising an amino acid sequence having at least 97% sequence identity to the amino acid sequence as set forth in SEQ ID NOS: 48, 49, 50, 51, 52, 65, 66, or 94. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having at least 98% sequence identity to the amino acid sequence as set forth in any one of SEQ ID NOs: 42, 43, 44, 45, 46, 47, 71, 72, or 93 and a light chain variable region comprising an amino acid sequence having at least 98% sequence identity to the amino acid sequence as set forth in SEQ ID NOS: 48, 49, 50, 51, 52, 65, 66, or 94. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having at least 99% sequence identity to the amino acid sequence as set forth in any one of SEQ ID NOs: 42, 43, 44, 45, 46, 47, 71, 72, or 93 and a light chain variable region comprising an amino acid sequence having 100% sequence identity to the amino acid sequence as set forth in SEQ ID NOS: 48, 49, 50, 51, 52, 65, 66, or 94.[000226] In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth SEQ ID NO: 2. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence as set forth SEQ ID NO: 2. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having at least 97% sequence identity to the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having at least 97% sequence identity to the amino acid sequence as set forth SEQ ID NO: 2. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having at least 99% sequence identity to the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having at least 99% sequence identity to the amino acid sequence as set forth SEQ ID NO: 2. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having 100% sequence identity to the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having 100% sequence identity to the amino acid sequence as set forth SEQ ID NO: 2. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having less than or equal to 10, 9, 8, 7, 6, 5, 4, 3, 2, 1 or 0 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having less than or equal to 10, 9, 8, 7, 6, 5, 4, 3, 2, 1 or 0 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 2. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having less than or equal to 10 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having less than or equal to 10 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 2. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having less than or equal to 7 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having less than or equal to 7 totalsubstitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 2. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having less than or equal to 5 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having less than or equal to 5 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 2. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having less than or equal to 3 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having less than or equal to 3 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 2. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having less than or equal to 2 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having less than or equal to 2 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 2. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having less than or equal to 1 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having less than or equal to 1 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 2.[000227] In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth SEQ ID NO: 48. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence as set forth SEQ ID NO: 48. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having at least 97% sequence identity to the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having at least 97% sequence identity to the amino acid sequence as set forth SEQ ID NO: 48. In some cases, the antibody provided herein comprises a heavy chain variable region comprising anamino acid sequence having at least 99% sequence identity to the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having at least 99% sequence identity to the amino acid sequence as set forth SEQ ID NO: 48. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having 100% sequence identity to the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having 100% sequence identity to the amino acid sequence as set forth SEQ ID NO: 48. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having less than or equal to 10, 9, 8, 7, 6, 5, 4, 3, 2, 1 or 0 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having less than or equal to 10, 9, 8, 7, 6, 5, 4, 3, 2, 1 or 0 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 48. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having less than or equal to 10 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having less than or equal to 10 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 48. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having less than or equal to 7 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having less than or equal to 7 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 48. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having less than or equal to 5 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having less than or equal to 5 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 48. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having less than or equal to 3 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having less than or equal to 3 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 48. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having less than or equal to 2 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising anamino acid sequence having less than or equal to 2 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 48. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having less than or equal to 1 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having less than or equal to 1 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 48[000228] In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth SEQ ID NO: 49. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence as set forth SEQ ID NO: 49. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having at least 97% sequence identity to the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having at least 97% sequence identity to the amino acid sequence as set forth SEQ ID NO: 49. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having at least 99% sequence identity to the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having at least 99% sequence identity to the amino acid sequence as set forth SEQ ID NO: 49. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having 100% sequence identity to the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having 100% sequence identity to the amino acid sequence as set forth SEQ ID NO: 49. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having less than or equal to 10, 9, 8, 7, 6, 5, 4, 3, 2, 1 or 0 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having less than or equal to 10, 9, 8, 7, 6, 5, 4, 3, 2, 1 or 0 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 49. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having less than or equal to 10 totalsubstitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having less than or equal to 10 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 49. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having less than or equal to 7 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having less than or equal to 7 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 49. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having less than or equal to 5 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having less than or equal to 5 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 49. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having less than or equal to 3 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having less than or equal to 3 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 49. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having less than or equal to 2 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having less than or equal to 2 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 49. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having less than or equal to 1 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having less than or equal to 1 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 49.[000229] In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth SEQ ID NO: 50. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence as setforth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence as set forth SEQ ID NO: 50. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having at least 97% sequence identity to the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having at least 97% sequence identity to the amino acid sequence as set forth SEQ ID NO: 50. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having at least 99% sequence identity to the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having at least 99% sequence identity to the amino acid sequence as set forth SEQ ID NO: 50. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having 100% sequence identity to the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having 100% sequence identity to the amino acid sequence as set forth SEQ ID NO: 50. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having less than or equal to 10, 9, 8, 7, 6, 5, 4, 3, 2, 1 or 0 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having less than or equal to 10, 9, 8, 7, 6, 5, 4, 3, 2, 1 or 0 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 50. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having less than or equal to 10 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having less than or equal to 10 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 50. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having less than or equal to 7 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having less than or equal to 7 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 50. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having less than or equal to 5 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having less than or equal to 5 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 50. In some cases, the antibody provided herein comprises a heavy chain variable region comprising anamino acid sequence having less than or equal to 3 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having less than or equal to 3 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 50. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having less than or equal to 2 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having less than or equal to 2 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 50. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having less than or equal to 1 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having less than or equal to 1 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 50.[000230] In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth SEQ ID NO: 51. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence as set forth SEQ ID NO: 51. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having at least 97% sequence identity to the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having at least 97% sequence identity to the amino acid sequence as set forth SEQ ID NO: 51. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having at least 99% sequence identity to the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having at least 99% sequence identity to the amino acid sequence as set forth SEQ ID NO: 51. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having 100% sequence identity to the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having 100% sequence identity to the amino acid sequence as set forth SEQ ID NO: 51. In some cases, theantibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having less than or equal to 10, 9, 8, 7, 6, 5, 4, 3, 2, 1 or 0 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having less than or equal to 10, 9, 8, 7, 6, 5, 4, 3, 2, 1 or 0 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 51. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having less than or equal to 10 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having less than or equal to 10 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 51. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having less than or equal to 7 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having less than or equal to 7 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 51. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having less than or equal to 5 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having less than or equal to 5 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 51. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having less than or equal to 3 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having less than or equal to 3 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 51. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having less than or equal to 2 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having less than or equal to 2 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 51. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having less than or equal to 1 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having less than or equal to 1 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 51[000231] In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth SEQ ID NO: 52. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence as set forth SEQ ID NO: 52. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having at least 97% sequence identity to the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having at least 97% sequence identity to the amino acid sequence as set forth SEQ ID NO: 52. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having at least 99% sequence identity to the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having at least 99% sequence identity to the amino acid sequence as set forth SEQ ID NO: 52. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having 100% sequence identity to the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having 100% sequence identity to the amino acid sequence as set forth SEQ ID NO: 52. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having less than or equal to 10, 9, 8, 7, 6, 5, 4, 3, 2, 1 or 0 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having less than or equal to 10, 9, 8, 7, 6, 5, 4, 3, 2, 1 or 0 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 52. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having less than or equal to 10 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having less than or equal to 10 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 52. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having less than or equal to 7 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having less than or equal to 7 totalsubstitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 52. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having less than or equal to 5 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having less than or equal to 5 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 52. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having less than or equal to 3 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having less than or equal to 3 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 52. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having less than or equal to 2 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having less than or equal to 2 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 52. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having less than or equal to 1 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having less than or equal to 1 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 52.[000232] In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth SEQ ID NO: 65. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence as set forth SEQ ID NO: 65. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having at least 97% sequence identity to the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having at least 97% sequence identity to the amino acid sequence as set forth SEQ ID NO: 65. In some cases, the antibody provided herein comprises a heavy chain variable region comprising anamino acid sequence having at least 99% sequence identity to the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having at least 99% sequence identity to the amino acid sequence as set forth SEQ ID NO: 65. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having 100% sequence identity to the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having 100% sequence identity to the amino acid sequence as set forth SEQ ID NO: 65. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having less than or equal to 10, 9, 8, 7, 6, 5, 4, 3, 2, 1 or 0 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having less than or equal to 10, 9, 8, 7, 6, 5, 4, 3, 2, 1 or 0 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 65. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having less than or equal to 10 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having less than or equal to 10 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 65. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having less than or equal to 7 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having less than or equal to 7 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 65. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having less than or equal to 5 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having less than or equal to 5 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 65. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having less than or equal to 3 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having less than or equal to 3 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 65. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having less than or equal to 2 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising anamino acid sequence having less than or equal to 2 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 65. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having less than or equal to 1 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having less than or equal to 1 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 65.[000233] In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth SEQ ID NO: 66. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence as set forth SEQ ID NO: 66. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having at least 97% sequence identity to the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having at least 97% sequence identity to the amino acid sequence as set forth SEQ ID NO: 66. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having at least 99% sequence identity to the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having at least 99% sequence identity to the amino acid sequence as set forth SEQ ID NO: 66. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having 100% sequence identity to the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having 100% sequence identity to the amino acid sequence as set forth SEQ ID NO: 66. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having less than or equal to 10, 9, 8, 7, 6, 5, 4, 3, 2, 1 or 0 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having less than or equal to 10, 9, 8, 7, 6, 5, 4, 3, 2, 1 or 0 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 66. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having less than or equal to 10 totalsubstitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having less than or equal to 10 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 66. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having less than or equal to 7 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having less than or equal to 7 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 66. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having less than or equal to 5 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having less than or equal to 5 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 66. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having less than or equal to 3 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having less than or equal to 3 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 66. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having less than or equal to 2 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having less than or equal to 2 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 66. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having less than or equal to 1 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 1, and a light chain variable region comprising an amino acid sequence having less than or equal to 1 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 66.[000234] In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth SEQ ID NO: 42, and a light chain variable region comprising an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth SEQ ID NO: 2. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence as setforth SEQ ID NO: 42, and a light chain variable region comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence as set forth SEQ ID NO: 2. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having at least 97% sequence identity to the amino acid sequence as set forth SEQ ID NO: 42, and a light chain variable region comprising an amino acid sequence having at least 97% sequence identity to the amino acid sequence as set forth SEQ ID NO: 2. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having at least 99% sequence identity to the amino acid sequence as set forth SEQ ID NO: 42, and a light chain variable region comprising an amino acid sequence having at least 99% sequence identity to the amino acid sequence as set forth SEQ ID NO: 2. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having 100% sequence identity to the amino acid sequence as set forth SEQ ID NO: 42, and a light chain variable region comprising an amino acid sequence having 100% sequence identity to the amino acid sequence as set forth SEQ ID NO: 2. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having less than or equal to 10, 9, 8, 7, 6, 5, 4, 3, 2, 1 or 0 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 42, and a light chain variable region comprising an amino acid sequence having less than or equal to 10, 9, 8, 7, 6, 5, 4, 3, 2, 1 or 0 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 2. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having less than or equal to 10 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 42, and a light chain variable region comprising an amino acid sequence having less than or equal to 10 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 2. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having less than or equal to 7 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 42, and a light chain variable region comprising an amino acid sequence having less than or equal to 7 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 2. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having less than or equal to 5 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 42, and a light chain variable region comprising an amino acid sequence having less than or equal to 5 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 2. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acidsequence having less than or equal to 3 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 42, and a light chain variable region comprising an amino acid sequence having less than or equal to 3 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 2. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having less than or equal to 2 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 42, and a light chain variable region comprising an amino acid sequence having less than or equal to 2 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 2. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having less than or equal to 1 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 42, and a light chain variable region comprising an amino acid sequence having less than or equal to 1 total substitutions, deletions, and / or insertions in the amino acid sequence as set forth SEQ ID NO: 2.[000235] In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth SEQ ID NO: 42, and a light chain variable region comprising an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence as set forth SEQ ID NO: 48. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence as set forth SEQ ID NO: 42, and a light chain variable region comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence as set forth SEQ ID NO: 48. In some cases, the antibody provided herein comprises a heavy chain variable region comprising an amino acid sequence having at least 97% sequence identity to the amino acid sequence as set forth SEQ ID NO: 42, and a light chain variable region comprising an amino acid sequence having at least 97% sequence identity to the amino acid sequence as set forth SEQ ID NO: 48. ...

Images